Tongji Hospital
华中科技大学同济医学院附属同济医院
Listed for 41 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.
Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.
Official links opened and checked on 2026-11-08.
Research at Tongji Hospital
Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.
Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed
- Nasopharyngeal carcinoma鼻咽癌8 papers led
- Oesophageal squamous cell carcinoma食管鳞状细胞癌10 papers led2 open trials led
- Hepatocellular carcinoma肝细胞癌238 papers led23 open trials led
- Stomach cancer胃癌45 papers led4 open trials led
- Hepatoblastoma肝母细胞瘤0 papers led
- Retinoblastoma视网膜母细胞瘤1 paper led
- Chordoma脊索瘤1 paper led
- Osteosarcoma骨肉瘤12 papers led
- Gastrointestinal stromal tumour胃肠道间质瘤3 papers led1 open trial led
- Neuroblastoma神经母细胞瘤8 papers led
- Ewing sarcoma尤文肉瘤0 papers led
- Multiple myeloma多发性骨髓瘤19 papers led3 open trials led
- B-cell acute lymphoblastic leukaemiaB 细胞急性淋巴细胞白血病7 papers led1 open trial led
- Aplastic anaemia再生障碍性贫血8 papers led
- Haemophagocytic lymphohistiocytosis噬血细胞性淋巴组织细胞增生症20 papers led1 open trial led
- Beta thalassaemiaβ 地中海贫血0 papers led
- Haemophilia A血友病 A4 papers led
- Thrombotic thrombocytopenic purpura血栓性血小板减少性紫癜6 papers led
- Neuromyelitis optica spectrum disorder视神经脊髓炎谱系疾病18 papers led7 open trials led
- IgG4-related diseaseIgG4相关性疾病11 papers led2 open trials led
- Myasthenia gravis重症肌无力17 papers led8 open trials led
- Moyamoya disease烟雾病3 papers led1 open trial led
- Biliary atresia胆道闭锁2 papers led1 open trial led
- Anti-NMDA receptor encephalitis抗 NMDA 受体脑炎2 papers led
- Idiopathic pulmonary fibrosis特发性肺纤维化14 papers led
- Lymphangioleiomyomatosis肺淋巴管平滑肌瘤病1 paper led
- Amyotrophic lateral sclerosis肌萎缩侧索硬化症11 papers led1 open trial led
- Fabry disease法布雷病0 papers led
- Duchenne muscular dystrophy杜氏肌营养不良2 papers led
- Behçet disease白塞病1 paper led
- Alport syndromeAlport 综合征2 papers led
- IgA nephropathyIgA 肾病21 papers led
- Gaucher disease戈谢病0 papers led
- Niemann–Pick disease type C尼曼-匹克病 C 型0 papers led
- Osteogenesis imperfecta成骨不全症0 papers led
- Primary biliary cholangitis原发性胆汁性胆管炎2 papers led
- Hirschsprung disease先天性巨结肠13 papers led
- Inherited epidermolysis bullosa遗传性大疱性表皮松解症0 papers led
- Hereditary angioedema遗传性血管性水肿1 paper led
- Familial adenomatous polyposis家族性腺瘤性息肉病0 papers led
- Leber hereditary optic neuropathyLeber 遗传性视神经病变2 papers led
Not listed for: Atypical haemolytic uraemic syndrome, Fanconi anaemia, Wilson disease, Takayasu arteritis, Hepatic echinococcosis, Spinal muscular atrophy, Pompe disease, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.
Cancer
Nasopharyngeal carcinoma
鼻咽癌Led 8 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.3%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
6 hospitals in Wuhan for nasopharyngeal carcinoma176 hospitals in China for nasopharyngeal carcinoma
Open trials with this hospital 4
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingQL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.
- Phase
- Phase 3
- Started
- 2025-05
- Registry
- NCT06749899
Age 18 years to 65 years (registered criteria)
Led by Sun Yat-sen University Cancer Center; 17 listed hospitals as study sitesChangsha, Chengdu, Dongguan, Foshan, Fuzhou, Guangzhou, Guiyang, Nanjing, Nanning, Shanghai, Tianjin, Wuhan, Xiamen, Zhongshan
- RecruitingA Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy
- Phase
- Phase 2
- Started
- 2025-04
- Registry
- NCT06839066
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesChangsha, Chengdu, Dongguan, Fuzhou, Ganzhou, Guangzhou, Hangzhou, Nanning, Shenzhen, Wuhan, Zhongshan
- RecruitingReduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy
- Phase
- Phase 3
- Started
- 2025-11
- Registry
- NCT07328841
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesChangsha, Guangzhou, Nanning, Shantou, Wuhan, Wuzhou, Zhongshan, Zhuhai
- RecruitingReduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response
- Phase
- Phase 3
- Started
- 2024-03
- Registry
- NCT06239727
Age 18 years to 65 years (registered criteria)
Led by Sun Yat-sen University Cancer Center; 21 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Dongguan, Foshan, Fuzhou, Guangzhou, Guiyang, Haikou, Hangzhou, Nanchang, Nanjing, Nanning, Shantou, Tianjin, Wuhan, Xi'an, Xiamen, Zhanjiang
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led8
- Retrospective study of a novel hematological parameter for predicting the survival of patients with nasopharyngeal carcinoma.
- Nasopharyngeal Carcinoma Subtype Discovery via Immune Cell Scores from Tumor Microenvironment.
- Ginsenoside Rg3 Sensitizes Nasopharyngeal Carcinoma Cells to Radiation by Suppressing Epithelial Mesenchymal Transition.
- CircSOX9 acts as a molecular sponge of miR-485-3p to promote the progression of nasopharyngeal carcinoma.
- MEX3A promotes nasopharyngeal carcinoma progression via the miR-3163/SCIN axis by regulating NF-κB signaling pathway.
- MiR196a-5p in extracellular vesicles released from human nasopharyngeal carcinoma enhance the phagocytosis and secretion of microglia by targeting ROCK1.
- Inhibition of PDK1 enhances radiosensitivity and reverses epithelial-mesenchymal transition in nasopharyngeal carcinoma.
- Induction of interleukin-6 by irradiation and its role in epithelial mesenchymal transition and radioresistance of nasopharyngeal carcinoma cells.
All its trials on ClinicalTrials.gov, any status14
- Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy
- QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.
- A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy
- Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response
- Cadonilimab (PD-1/CTLA-4 Bispecific Blockade) and Chemoradiotherapy in Nasopharyngeal Carcinoma (GEMSTONE)
- KSD-101 Therapy for EBV-associated Nasopharyngeal Carcinoma: an Exploratory Clinical Trial
- Phase III Trial of Concurrent Chemotherapy Alone in Patients With Low-risk Nasopharyngeal Carcinoma
- PD-1 Blockade Combined With De-intensified Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma
- PD-1 Antibody Versus Best Supportive Care After Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma
- The Efficacy and Safety Study of TORIPALIMAB INJECTION Combined With Chemotherapy for Nasophapyngeal Cancer
- The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC
- Cisplatin Plus Docetaxel Versus Cetuximab, Cisplatin, and Docetaxel in Metastatic Nasopharyngeal Carcinoma
- Trial Evaluating Maintenance Chemotherapy for Metastatic Nasopharyngeal Carcinoma
- The Role of Concurrent Chemotherapy for Lower Risk Locally Advanced Nasopharyngeal Carcinoma(NPC) in the Era of IMRT
More papers found outside PubMed (not counted)6
- Development and Validation of a Multi‐Omics Model Integrating MR Radiomics and Immune Scores for Prognostic Prediction in Locally Advanced Nasopharyngeal Carcinoma
- PD-1 blockade with toripalimab incorporated into induction chemotherapy and radiotherapy with or without concurrent cisplatin in locoregionally advanced nasopharyngeal carcinoma (DIAMOND): A multicenter, non-inferiority, phase 3, randomized
- Adjuvant PD-1 blockade with camrelizumab in high-risk locoregionally advanced nasopharyngeal carcinoma (DIPPER): A multicenter, open-label, phase 3, randomized controlled trial.
- PD-1 blockade with camrelizumab after chemoradiotherapy in nasopharyngeal carcinoma.
- Camrelizumab versus placebo combined with gemcitabine and cisplatin for recurrent or metastatic nasopharyngeal carcinoma: A randomized, double-blind, phase 3 trial.
- Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: A phase 3, multicenter, randomized controlled trial.
Cancer
Oesophageal squamous cell carcinoma
食管鳞状细胞癌Led 10 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.3%.
- Open trials as a site
- 0
- led by another institution
5 hospitals in Wuhan for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma
Open trials with this hospital 2
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingDeep Learning Model Predicts Pathological Complete Response of Esophageal Squamous Cell Carcinoma Following Neoadjuvant Immunochemotherapy
- Phase
- Not given
- Started
- 2025-03
- Registry
- NCT07088354
Age 18 years to Not stated (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingNeoadjuvant Cardonilizumab Combined With Neoadjuvant Chemoradiotherapy Can Resect Locally Advanced Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2024-01
- Registry
- NCT07699185
Age 18 years to 75 years (registered criteria)
Led by Tongji HospitalWuhan
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led10
- Clinical efficacy and biomarkers of neoadjuvant chemoimmunotherapy in locally advanced esophageal squamous cell carcinoma.
- SLC43A2 and NFκB signaling pathway regulate methionine/cystine restriction-induced ferroptosis in esophageal squamous cell carcinoma via a feedback loop.
- BBOX1-AS1 Activates Hedgehog Signaling Pathway to Facilitate the Proliferation and Stemness of Esophageal Squamous Cell Carcinoma Cells via miR-506-5p/EIF5A/PTCH1 Axis.
- Cost-effectiveness of sintilimab plus chemotherapy versus chemotherapy alone as first-line treatment of locally advanced or metastatic oesophageal squamous cell carcinoma.
- Long intergenic non-protein coding RNA 00858 participates in the occurrence and development of esophageal squamous cell carcinoma through the activation of the FTO-m6A-MYC axis by recruiting ZNF184.
- Diagnosis and treatment of right ventricular metastasis from esophageal squamous cell carcinoma: An unusual case report and a literature review.
- Research Progress on the Predicting Factors and Coping Strategies for Postoperative Recurrence of Esophageal Cancer.
- Esophagus cancer and essential trace elements.
- GTF2E2 is a novel biomarker for recurrence after surgery and promotes progression of esophageal squamous cell carcinoma via miR-139-5p/GTF2E2/FUS axis.
- An extremely atypical presentation of esophageal squamous cell carcinoma with pancreatic and hepatic metastases: A case report and overview of the literature.
All its trials on ClinicalTrials.gov, any status9
- Deep Learning Model Predicts Pathological Complete Response of Esophageal Squamous Cell Carcinoma Following Neoadjuvant Immunochemotherapy
- Neoadjuvant Cardonilizumab Combined With Neoadjuvant Chemoradiotherapy Can Resect Locally Advanced Esophageal Squamous Cell Carcinoma
- Postoperative Radiotherapy and Lymph Node Dissection After Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma
- Neoadjuvant Immunotherapy (PD-1 / PD-L1) Combined With Chemotherapy for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma: a Single Center, Prospective, Open, One Arm Exploratory Clinical Study
- Cardenilimab Combined With Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma
- BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Carcinoma
- Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension Study
- The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC
- Irinotecan Plus S1 Versus S1 in Patients With Previously Treated Advanced Esophageal Cancer: ESWN 01 Trial
More papers found outside PubMed (not counted)15
- Tislelizumab combined with radiotherapy for unresectable locally advanced esophageal squamous cell carcinoma: A prospective, single-arm, phase II study (TREC)
- Letter to the Editor: Human papillomavirus 16 infection in patients with esophageal squamous cell carcinoma undergoing chemoradiotherapy
- Neoadjuvant Immunotherapy combined with Chemoradiotherapy VS. Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma(cStageII-III): Study Protocol For A Multi-center Prospective Randomized Clinical Trial
- Additional file 2 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma
- Additional file 3 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma
- Additional file 4 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma
- Additional file 5 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma
- miR-139-5p mediates TGIF1 to regulate the TGFβ pathway and inhibit growth of esophageal squamous cell carcinoma cells
- Additional file 1 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration
- Additional file 2 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration
- Additional file 4 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration
- Additional file 5 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration
- Design and synthesis of copper nanoparticles for the treatment of human esophageal cancer: introducing a novel chemotherapeutic supplement
- Downregulation of long noncoding RNA breast cancer anti-estrogen resistance 4 inhibits cell proliferation, invasion, and migration in esophageal squamous cell carcinoma by regulating the microRNA-181c-5p/LIM and SH3 protein 1 axis
- LncRNA HCP5 promotes malignant cell behaviors in esophageal squamous cell carcinoma via the PI3K/AKT/mTOR signaling
Cancer
Hepatocellular carcinoma
肝细胞癌Led 238 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 1.6%.
6 hospitals in Wuhan for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma
Open trials with this hospital 30
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingTislelizumab Combined With Huaier Granule as First-line Treatment for Unresectable Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2026-04
- Registry
- NCT07413354
Age 18 years to Not stated (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingIparomlimab and Tuvonralimab as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With High Risk of Recurrence
- Phase
- Phase 2
- Started
- 2025-08
- Registry
- NCT06954116
Age 18 years to 75 years (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingAI-Based Prediction of HCC Recurrence Patterns After Resection (APAR)
- Phase
- Not given
- Started
- 2025-06
- Registry
- NCT07062380
Age 18 years to 75 years (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingApatinib Mesylate and Camrelizumab Combined With TACE as Neoadjuvant Therapy for Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2025-12
- Registry
- NCT07154082
Age 18 years to 70 years (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingMultimodal Deep Learning for Postoperative Liver Cancer Risk Stratification and Intervention
- Phase
- Phase 1/Phase 2
- Started
- 2025-10
- Registry
- NCT07282184
Age 18 years to 75 years (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingImpact of Splenectomy on the Efficacy of Targeted Therapy and Immunotherapy in Unresectable HCC Patients With Cirrhotic Portal Hypertension
- Phase
- Not given
- Started
- 2024-03
- Registry
- NCT06280313
Age 18 years to 75 years (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingPrecision Adjuvant Therapy After Surgery for Hepatocellular Carcinoma
- Phase
- Phase 4
- Started
- 2024-04
- Registry
- NCT06311929
Age 18 years to 75 years (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingPalliative Hepatectomy Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular Carcinoma
- Phase
- Phase 1
- Started
- 2024-06
- Registry
- NCT06470256
Age 18 years to 75 years (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingCirculating Tumor Mitochondrial DNA (ct-mtDNA) As a Biomarker for Hepatocellular Carcinoma Recurrence Surveillance
- Phase
- Not given
- Started
- 2024-11
- Registry
- NCT06653062
Age 18 years to Not stated (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingMultimodalomics-based Construction of Spatiotemporal Characteristics of Dynamic Liver Cancer Microenvironment to Characterize the Clinical Application of Immune Mechanisms in Liver Cancer
- Phase
- Not given
- Started
- 2024-10
- Registry
- NCT07838415
Age 18 years to 80 years (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingHAIC, Lenvatinib, and Cadonilimab as Conversion Therapy for Initially Unresectable Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2023-12
- Registry
- NCT06187961
Age 18 years to Not stated (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingAmbispective Cohort Study of Precision Medicine for Primary Hepatobiliary Cancer Based on Next-generation Sequencing
- Phase
- Not given
- Started
- 2020-05
- Registry
- NCT05520788
Age 18 years to Not stated (registered criteria)
Led by Tongji HospitalWuhan
- Not yet recruitingLocal Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer
- Phase
- Phase 3
- Started
- 2026-05
- Registry
- NCT07537946
Age 18 years to 75 years (registered criteria)
Led by Tongji HospitalWuhan
- Not yet recruitingSurgery Plus Systemic Therapy for Liver Cancer With Extrahepatic Metastases
- Phase
- N/A
- Started
- 2026-04
- Registry
- NCT07537959
Age 18 years to 75 years (registered criteria)
Led by Tongji HospitalWuhan
- Not yet recruitingDenosumab Strategy for Liver Cancer With Bone Metastases
- Phase
- Phase 2
- Started
- 2026-05
- Registry
- NCT07537972
Age 18 years to 75 years (registered criteria)
Led by Tongji HospitalWuhan
- Not yet recruitingAI-Guided First-Line Immunotherapy Selection in Unresectable Hepatocellular Carcinoma
- Phase
- N/A
- Started
- 2026-10
- Registry
- NCT07729618
Age 18 years to Not stated (registered criteria)
Led by Tongji HospitalWuhan
- Not yet recruitingAI-Guided Surveillance and Curative Salvage of Recurrence After Hepatocellular Carcinoma Resection or Ablation
- Phase
- N/A
- Started
- 2026-10
- Registry
- NCT07732504
Age 18 years to Not stated (registered criteria)
Led by Tongji HospitalWuhan
- Not yet recruitingQL1706 As Second-line Treatment in Patients with Advanced Hepatocellular Carcinoma
- Phase
- Phase 1
- Started
- 2025-02
- Registry
- NCT06822985
Age 18 years to 75 years (registered criteria)
Led by Tongji HospitalWuhan
- Not yet recruitingIcaritin Soft Capsules+TACE+Immunotherapy+Targeted Therapy Versus TACE+Immunotherapy+Targeted Therapy for Unresectable Hepatocellular Carcinoma
- Phase
- Phase 1/Phase 2
- Started
- 2025-04
- Registry
- NCT06896396
Age 18 years to 75 years (registered criteria)
Led by Tongji HospitalWuhan
- Not yet recruitingTauroursodeoxycholic Acid Combined With PD-1/PD-L1 Immunotherapy in Advanced Hepatocellular Carcinoma: A Prospective Study
- Phase
- Phase 2
- Started
- 2025-07
- Registry
- NCT07064668
Age 18 years to 80 years (registered criteria)
Led by Tongji HospitalWuhan
- Not yet recruitingTACE Combined With Tislelizumab, Lenvatinib, and Carvedilol for Unresectable HCC With Cirrhotic Portal Hypertension
- Phase
- Phase 2
- Started
- 2025-12
- Registry
- NCT07350070
Age 18 years to 75 years (registered criteria)
Led by Tongji Hospital; 4 listed hospitals as study sitesFuzhou, Jinan, Nanning, Qingdao, Wuhan
- Not yet recruitingPredictive Value of Minimal Residual Disease for Postoperative Recurrence and Adjuvant PD-1 Inhibitor in HCC
- Phase
- N/A
- Started
- 2025-12
- Registry
- NCT07350824
Age 18 years to 75 years (registered criteria)
Led by Tongji HospitalWuhan
- Not yet recruitingPostoperative Adjuvant Sintilimab in Hepatocellular Carcinoma With Microvascular Invasion
- Phase
- Phase 3
- Started
- 2024-06
- Registry
- NCT06089369
Age 18 years to 75 years (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingPhase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
- Phase
- Phase 1
- Started
- 2025-11
- Registry
- NCT07176650
Age 18 years to 65 years (registered criteria)
Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Bengbu, Changchun, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Xi'an, Zhengzhou
- RecruitingABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
- Phase
- Phase 2
- Started
- 2025-06
- Registry
- NCT07327034
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 39 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Ganzhou, Guangzhou, Guilin, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shenyang, Tianjin, Wuhan, Xi'an, Xuzhou, Yinchuan, Zhengzhou
- RecruitingcfDNA Methylation for Liver Cancer Recurrence Detection
- Phase
- Not given
- Started
- 2025-09
- Registry
- NCT07466602
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteWuhan
- RecruitingPhase 2 Study of WGI-0301 for Advanced HCC
- Phase
- Phase 2
- Started
- 2024-07
- Registry
- NCT06309485
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesChangsha, Chengdu, Hangzhou, Harbin, Nanchang, Wuhan
- RecruitingA Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2024-07
- Registry
- NCT06427941
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Nanchang, Nanning, Shijiazhuang, Wenzhou, Wuhan, Xuzhou
- RecruitingCT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical Resection
- Phase
- Phase 1
- Started
- 2023-10
- Registry
- NCT06560827
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Shanghai, Shenyang, Tianjin, Wuhan, Zhengzhou
- Enrolling by invitationA Phase 2, Open-Label Study of ABSK-011 Combined Atezolizumab or SOC in HCC Patients
- Phase
- Phase 2
- Started
- 2021-12
- Registry
- NCT05441475
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteWuhan
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led238
- Long-Term Survival and Beneficiaries of Adjuvant Anti-PD-1 Therapy in Resected Hepatocellular Carcinoma.
- Fibrosis-driven hepatocarcinogenesis, metastasis and immune evasion: Mechanisms and therapeutic targets.
- Research progress on the regulation of microRNAs by traditional Chinese medicine in the prevention and treatment of hepatocellular carcinoma.
- NEK7-induced phosphorylation of EGFR on serine 1070 drives the acquired lenvatinib resistance in hepatocellular carcinoma.
- Clinical and economic outcomes of robotic-assisted, laparoscopic, and open liver resection in BCLC 0/A hepatocellular carcinoma: a nationwide cohort study.
- Vessels encapsulating tumor clusters is associated with impaired efficacy of adjuvant immunotherapy in resected hepatocellular carcinoma.
- A novel pathologic scoring system for predicting postoperative recurrence in BCLC stage 0-A hepatocellular carcinoma patients: a nationwide multicenter study.
- Hafnium Metal-Organic Framework-Based Glutamine Metabolism Disruptor For Potentiating Radio-Immunotherapy in MYC-Amplified Hepatocellular Carcinoma.
- m6A-Mediated TMCO3 Promotes Hepatocellular Carcinoma Progression by Facilitating the Membrane Translocation and Activation of AKT.
- CKAP4 in hepatocellular carcinoma: competitive RETREG1/FAM134B binding, reticulophagy regulation, and cancer progression.
- Liver resection versus transarterial chemoembolization plus PD-1 inhibitors and lenvatinib for hepatocellular carcinoma with portal vein tumour thrombus.
- Risk factors for hepatocellular carcinoma rupture: multicentre retrospective study.
- From genes to therapy: a lipid Metabolism-Related genetic risk model predicts HCC outcomes and enhances immunotherapy.
- Cost-effectiveness of atezolizumab plus bevacizumab versus sorafenib as first-line therapy in unresectable hepatocellular carcinoma in the US and Chinese setting: a modelling comparison study.
- The important role of myeloid-derived suppressor cells: From hepatitis to liver cancer.
- Evaluation of anti-tumor activity of borated camptothecin derivatives targeting topoisomerase 1 against hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
- Lenvatinib promotes hepatocellular carcinoma pyroptosis by regulating GSDME palmitoylation.
- FBXO22 promotes HCC angiogenesis and metastasis via RPS5/AKT/HIF-1α/VEGF-A signaling axis.
- Senescent fibroblasts secrete CTHRC1 to promote cancer stemness in hepatocellular carcinoma.
- The cancer-associated fibroblast facilitates YAP liquid-liquid phase separation to promote cancer cell stemness in HCC.
- Targeting FAM134B-DDX3X axis inhibiting AKT signaling in hepatocellular carcinoma.
- The Hippo-YAP signaling pathway promotes hepatocellular carcinoma progression by inducing FHL3 expression.
- IFNγ augments TKI efficacy by alleviating protein unfolding stress to promote GSDME-mediated pyroptosis in hepatocellular carcinoma.
- Disrupting CCDC137-mediated LZTS2 and β-TrCP interaction in the nucleus inhibits hepatocellular carcinoma development via β-catenin and AKT.
- Cancer-associated fibroblast-derived extracellular vesicles facilitate metastasis in hepatocellular carcinoma by delivering CTGF.
- Ribosomal protein L6 suppresses hepatocellular carcinoma by modulating FBXO22-mediated p53 degradation.
- Targeting TM4SF1 promotes tumor senescence enhancing CD8+ T cell cytotoxic function in hepatocellular carcinoma.
- MET promotes hepatocellular carcinoma development through the promotion of TRIB3-mediated FOXO1 degradation.
- Oncofetal dual‑specificity phosphatase 9 drives stem-like properties through ERK1/2-PPARG-SCD axis-mediated lipid metabolism in hepatocellular carcinoma.
- Machine Learning-based Gene Biomarker Identification for Improving Prognosis and Therapy in Hepatocellular Carcinoma.
- Seven Hypoxia and Immune-Related Features Predict Prognosis in Patients with Hepatocellular Carcinoma.
- Adjuvant PD-1 inhibitors improve recurrence and survival outcomes in high-risk hepatocellular carcinoma patients after curative hepatectomy.
- Assessment of viable tumours by [68Ga]Ga-FAPI-04 PET/CT after local regional treatment in patients with hepatocellular carcinoma.
- Differentiating atypical hepatocellular carcinoma from focal nodular Hyperplasia: The value of Kupffer phase imaging with Sonazoid-Contrast-Enhanced ultrasound compared to Gadodiamide-Enhanced MRI.
- Synchronous hepatectomy and splenectomy for patients with BCLC stage 0/A hepatocellular carcinoma and clinically significant portal hypertension: A multicenter retrospective cohort study.
- Efficacy and safety of preoperative TACE in hepatocellular carcinoma beyond Milan criteria: A propensity score matching analysis.
- An immune-related signature based on molecular subtypes for predicting the prognosis and immunotherapy efficacy of hepatocellular carcinoma.
- Post-translational acylation modulates immunosuppression and immunotherapy efficacy in hepatocellular carcinoma.
- E-twenty-six-specific sequence variant 5 (ETV5) facilitates hepatocellular carcinoma progression and metastasis through enhancing polymorphonuclear myeloid-derived suppressor cell (PMN-MDSC)-mediated immunosuppression.
- The impact of resection margin width on surgical outcomes for solitary hepatocellular carcinoma with sub-classification of microvascular invasion.
- Short-term starvation boosts anti-PD-L1 therapy by reshaping tumor-associated macrophages in hepatocellular carcinoma.
- Regulatory role of gut microbiota in immunotherapy of hepatocellular carcinoma.
- Immunotherapy resistance in MASLD-related hepatocellular carcinoma: special immune microenvironment and gut microbiota.
- Association between Vessels Encapsulating Tumor Clusters and Circulating Tumor Cells in Hepatocellular Carcinoma: Clinical Evidence and Risk Model Development.
- TGM2-mediated histone serotonylation promotes HCC progression via MYC signalling pathway.
- EIF4A3-Mediated downregulation of circPTEN promotes hepatocellular carcinoma progression through the miR-1289/RBM38 Axis.
- Involvement of ferroptosis in metabolic dysfunction-associated steatohepatitis-related liver diseases.
- Synthesis and Preclinical Evaluation of Dual-Specific Probe Targeting Glypican-3 and Prostate-Specific Membrane Antigen for Hepatocellular Carcinoma PET Imaging.
- 18F-FDG Versus Tissue Factor-Targeted PET/CT in Longitudinal Evaluation of the Formation of DEN-Induced Rat Hepatocellular Carcinoma.
- VRK2 targeting potentiates anti-PD-1 immunotherapy in hepatocellular carcinoma through MYC destabilization.
- Circ-PAN3 facilitates hepatocellular carcinoma growth via sponging miR-153 and upregulating cyclin D1.
- Overexpression of ORAOV1 and its association with immunotherapy resistance in hepatocellular carcinoma.
- Perfluorobutane-enhanced US Targeting M2 Tumor-associated Macrophages for Predicting Programmed Cell Death-1 Response in Hepatocellular Carcinoma.
- PARK7-driven IGF2BP3-K76 lactylation mediates ferroptosis and HAIC resistance in hepatocellular carcinoma.
- Riplet promotes lipid metabolism changes associated with CD8 T cell exhaustion and anti-PD-1 resistance in hepatocellular carcinoma.
- Machine learning models for predicting postoperative peritoneal metastasis after hepatocellular carcinoma rupture: a multicenter cohort study in China.
- 18F-5-fluoro-aminosuberic acid PET/CT imaging of oxidative-stress features during the formation of DEN-induced rat hepatocellular carcinoma.
- Prognostic model for unresectable hepatocellular carcinoma treated with transarterial therapy plus TKIs and anti-PD-1 antibodies.
- Revisiting the role of local treatments in the era of targeted therapy and immunotherapy for hepatocellular carcinoma.
- Predictive factors and prognostic models for Hepatic arterial infusion chemotherapy in Hepatocellular carcinoma: a comprehensive review.
- Impact of intraperitoneal lavage with lobaplatin on survival in patients undergoing hepatectomy for ruptured hepatocellular carcinoma.
- "Trinity" Comprehensively Regulates the Tumor Microenvironment of Lipid-Coated CaCO3@CuO2 Nanoparticles Induces "Cuproptosis" in HCC.
- CEUS in prediction of early recurrence of hepatocellular carcinoma after curative resection and to stratify the risk of early recurrence: a retrospective observational study.
- Predicting Ki-67 expression in hepatocellular carcinoma: nomogram based on clinical factors and contrast-enhanced ultrasound radiomics signatures.
- Lactylation-Driven IGF2BP3-Mediated Serine Metabolism Reprogramming and RNA m6A-Modification Promotes Lenvatinib Resistance in HCC.
- m6A-Dependent ITIH1 Regulated by TGF-β Acts as a Target for Hepatocellular Carcinoma Progression.
- SOX12 Facilitates Hepatocellular Carcinoma Progression and Metastasis through Promoting Regulatory T-Cells Infiltration and Immunosuppression.
- YTHDF2 Is a Therapeutic Target for HCC by Suppressing Immune Evasion and Angiogenesis Through ETV5/PD-L1/VEGFA Axis.
- Liver resection versus microwave ablation for solitary and small (≤ 3 cm) HCC with early recurrence in different stages of liver cirrhosis: A propensity score matching study.
- A pathologic scoring system for predicting postoperative prognosis in patients with ruptured hepatocellular carcinoma.
- Inhibition of PTPRE suppresses tumor progression and improves sorafenib response in hepatocellular carcinoma.
- Targeting N4-acetylcytidine suppresses hepatocellular carcinoma progression by repressing eEF2-mediated HMGB2 mRNA translation.
- GPR56 facilitates hepatocellular carcinoma metastasis by promoting the TGF-β signaling pathway.
- TNKS1BP1 facilitates ubiquitination of CNOT4 by TRIM21 to promote hepatocellular carcinoma progression and immune evasion.
- HMGB1 promotes mitochondrial transfer between hepatocellular carcinoma cells through RHOT1 and RAC1 under hypoxia.
- Bifidobacterium longum promotes postoperative liver function recovery in patients with hepatocellular carcinoma.
- The switch triggering the invasion process: Lipid metabolism in the metastasis of hepatocellular carcinoma.
- SP1-activated USP27X-AS1 promotes hepatocellular carcinoma progression via USP7-mediated AKT stabilisation.
- Liquid-liquid phase separation-related lncRNA prognostic signature and ZNF32-AS2 as a novel biomarker in hepatocellular carcinoma.
- A Randomized Comparison of Transradial and Transfemoral Approach in Hepatic Arterial Infusion Chemotherapy.
- New insights into the mechanism of resistance to lenvatinib and strategies for lenvatinib sensitization in hepatocellular carcinoma.
- Regulatory T cell: a double-edged sword from metabolic-dysfunction-associated steatohepatitis to hepatocellular carcinoma.
- The predictive value of next generation sequencing for matching advanced hepatocellular carcinoma patients to targeted and immunotherapy.
- Nomograms confirm serum IL-6 and CRP as predictors of immune checkpoint inhibitor efficacy in unresectable hepatocellular carcinoma.
- TGF-β1-Induced SOX18 Elevation Promotes Hepatocellular Carcinoma Progression and Metastasis Through Transcriptionally Upregulating PD-L1 and CXCL12.
- Targeting MMP9 in CTNNB1 mutant hepatocellular carcinoma restores CD8+ T cell-mediated antitumour immunity and improves anti-PD-1 efficacy.
- Distinctly altered lipid components in hepatocellular carcinoma relate to impaired T cell-dependent antitumor immunity.
- The dual role of regulatory T cells in hepatitis B virus infection and related hepatocellular carcinoma.
- SRSF10 facilitates HCC growth and metastasis by suppressing CD8+T cell infiltration and targeting SRSF10 enhances anti-PD-L1 therapy.
- SLC41A1 overexpression correlates with immune cell infiltration in HCC and promotes its malignant progression.
- The Prognostic and Therapeutic Roles of ARL-6 Gene in Hepatocellular Carcinoma.
- Transcription factor E2F4 facilitates SUMOylation to promote HCC progression through interaction with LIN9.
- Contradictory Role of Gadd45β in Liver Diseases.
- Postoperative lenvatinib + PD-1 blockade reduces early tumor recurrence in hepatocellular carcinoma with microvascular invasion (Barcelona Clinic Liver Cancer stage 0 or A): a propensity score matching analysis.
- N6-methyladenosine modification of circular RNA circASH2L suppresses growth and metastasis in hepatocellular carcinoma through regulating hsa-miR-525-3p/MTUS2 axis.
- Systemic chemotherapy plus transarterial chemoembolization versus systemic chemotherapy alone for unresectable intrahepatic cholangiocarcinoma: a multicenter retrospective cohort study.
- Improvements in advanced hepatocellular carcinoma to repeat implementation of primary protocol after cancer progression occurs following sequential systemic therapy and a clinical trial: A case report.
- USP26 as a hepatitis B virus-induced deubiquitinase primes hepatocellular carcinogenesis by epigenetic remodeling.
- Surveillance Following Hepatitis B Surface Antigen Loss: An Issue Requiring Attention.
- NLR stability predicts response to immune checkpoint inhibitors in advanced hepatocellular carcinoma.
- Prognosis and safety of laparoscopic hepatectomy for BCLC stage 0/A hepatocellular carcinoma with clinically significant portal hypertension: a multicenter, propensity score-matched study.
- Preclinical evaluation of radiolabeled tissue factor-targeted peptide for theranostics of hepatocellular carcinoma post percutaneous ethanol injection.
- Understanding gut dysbiosis for hepatocellular carcinoma diagnosis and treatment.
- Comparison of Sonazoid-Contrast‑Enhanced Ultrasound and Gd‑EOB‑DTPA‑Enhanced MRI for Predicting Microvascular Invasion in Hepatocellular Carcinoma.
- Is ALPPS still appropriate for large or locally advanced hepatocellular carcinoma in an era of targeted agents and immunotherapy?
- Core-shell cisplatin/SiO2 nanocapsules combined with PTC-209 overcome chemotherapy-Acquired and intrinsic resistance in hepatocellular carcinoma.
- Bone Lesion-Derived Extracellular Vesicles Fuel Prometastatic Cascades in Hepatocellular Carcinoma by Transferring ALKBH5-Targeting miR-3190-5p.
- A Prospective Study Using Propensity Score Matching to Compare Long-term Survival Outcomes After Robotic-assisted, Laparoscopic, or Open Liver Resection for Patients With BCLC Stage 0-A Hepatocellular Carcinoma.
- Baseline Albumin-Bilirubin grade as a predictor of response and outcome of regorafenib therapy in patients with hepatocellular carcinoma: a systematic review and meta-analysis.
- MicroRNA-188-5p inhibits hepatocellular carcinoma proliferation and migration by targeting forkhead box N2.
- Identification and in vitro and in vivo validation of the key role of GSDME in pyroptosis-related genes signature in hepatocellular carcinoma.
- CEUS LI-RADS for diagnosis of hepatocellular carcinoma in individuals without LI-RADS-defined hepatocellular carcinoma risk factors.
- Targeting LINC01607 sensitizes hepatocellular carcinoma to Lenvatinib via suppressing mitophagy.
- Collagen I-DDR1 signaling promotes hepatocellular carcinoma cell stemness via Hippo signaling repression.
- The role of pyroptosis in hepatocellular carcinoma.
- LINC01980 induced by TGF-beta promotes hepatocellular carcinoma metastasis via miR-376b-5p/E2F5 axis.
- TACE plus PD-1 successfully achieves conversion therapy for unresectable HCC with multiple macrovascular invasion: Case report.
- Combined immunotherapy for hepatocellular carcinoma: How to maximize immune checkpoint blockade synergic anti-tumor effect.
- Scientific Hepatectomy for Hepatocellular Carcinoma.
- DLAT as a Cuproptosis Promoter and a Molecular Target of Elesclomol in Hepatocellular Carcinoma.
- Prognostic Factors of Liver Transplantation for Hepatocellular Carcinoma: A Surveillance, Epidemiology, and End Results (SEER) Database Analysis.
- Long noncoding RNA MAPKAPK5-AS1 promotes metastasis through regulation miR-376b-5p/ECT2 axis in hepatocellular carcinoma.
- A nomogram for preoperative prediction of microvascular invasion in ruptured hepatocellular carcinoma.
- Repeat hepatectomy versus microwave ablation for solitary and small (≤3 cm) recurrent hepatocellular carcinoma with early or late recurrence: A propensity score matched study.
- Clinically significant portal hypertension (CSPH) on early-stage HCC following hepatectomy: What's the impact?
- Neoadjuvant drug-eluting bead transarterial chemoembolization and tislelizumab therapy for resectable or borderline resectable hepatocellular carcinoma: A propensity score matching analysis.
- HCC treated with immune checkpoint inhibitors: a hyper-enhanced rim on Sonazoid-CEUS Kupffer phase images is a predictor of tumor response.
- Identifying the programmed cell death index of hepatocellular carcinoma for prognosis and therapy response improvement by machine learning: a bioinformatics analysis and experimental validation.
- Case Report: Successful conversion and salvage resection of huge hepatocellular carcinoma with portal vein tumor thrombosis and intrahepatic metastasis via sequential hepatic arterial infusion chemotherapy, lenvatinib plus PD-1 antibody fol
- Case Report: Durable complete response of metastatic hepatocellular carcinoma with asymptomatic hyperamylasemia to combined immunotherapy of anti-cytotoxic T lymphocyte-associated antigen 4 plus anti-programmed cell death-1 antibodies.
- Identification of molecular pattern and prognostic risk model based on ligand-receptor pairs in liver cancer.
- Postoperative adjuvant tyrosine kinase inhibitors combined with anti-PD-1 antibodies improves surgical outcomes for hepatocellular carcinoma with high-risk recurrent factors.
- Conversion therapy for advanced hepatocellular carcinoma with vascular invasion: a comprehensive review.
- Alkaline phosphatase combined with γ-glutamyl transferase is an independent predictor of prognosis of hepatocellular carcinoma patients receiving programmed death-1 inhibitors.
- Radiation therapy in the era of immune treatment for hepatocellular carcinoma.
- Identification of PANoptosis-Based Prognostic Signature for Predicting Efficacy of Immunotherapy and Chemotherapy in Hepatocellular Carcinoma.
- Des-gamma-carboxy prothrombin is a promising biomarker of hepatocellular carcinoma and a predictor of complications in patients with chronic liver diseases.
- Differential requirement of Hippo cascade during CTNNB1 or AXIN1 mutation-driven hepatocarcinogenesis.
- Targeting VPS72 inhibits ACTL6A/MYC axis activity in HCC progression.
- Cost-effectiveness of nivolumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma.
- CENPA functions as a transcriptional regulator to promote hepatocellular carcinoma progression via cooperating with YY1.
- Comprehensive Analysis of Sideroflexin 4 in Hepatocellular Carcinoma by Bioinformatics and Experiments.
- Histone H3 activates caspase-1 and promotes proliferation and metastasis in hepatocellular carcinoma.
- Conventional and drug-eluting beads transarterial chemoembolization in patients with unresectable intrahepatic cholangiocarcinoma: a systematic review and pooled analysis.
- Prognostic value of preoperative circulating tumor cells for hepatocellular carcinoma with portal vein tumor thrombosis: A propensity score analysis.
- Risk Factors of Positive Resection Margin in Hepatectomy for Resectable Ruptured Hepatocellular Carcinoma: Risk Prediction and Prognosis.
- Synergistic efficacy of simultaneous anti-TGF-β/VEGF bispecific antibody and PD-1 blockade in cancer therapy.
- FGF19/FGFR4-mediated elevation of ETV4 facilitates hepatocellular carcinoma metastasis by upregulating PD-L1 and CCL2.
- The stromal-tumor amplifying STC1-Notch1 feedforward signal promotes the stemness of hepatocellular carcinoma.
- LINC01608 activated by YY1 facilitate hepatocellular carcinoma progression by modulating the EGFR/ERK axis.
- Intelectin-1 is a novel prognostic biomarker for hepatocellular carcinoma.
- MTDH-stabilized DDX17 promotes tumor initiation and progression through interacting with YB1 to induce EGFR transcription in Hepatocellular Carcinoma.
- A micropeptide JunBP regulated by TGF-β promotes hepatocellular carcinoma metastasis.
- Diagnostic Value of OPNI in Hepatocellular Carcinoma.
- The correlation between tumor-associated macrophages and the prognosis of east Asian hepatocellular carcinoma patients: A systematic review and meta-analysis.
- Targeting super enhancers for liver disease: a review.
- METTL5 serves as a diagnostic and prognostic biomarker in hepatocellular carcinoma by influencing the immune microenvironment.
- Dynamic contrast-enhanced ultrasonography with sonazoid predicts microvascular invasion in early-stage hepatocellular carcinoma.
- MYC-activated LINC00607 promotes hepatocellular carcinoma progression by regulating the miR-584-3p/ROCK1 axis.
- Identification of an EMT-related lncRNA signature and LINC01116 as an immune-related oncogene in hepatocellular carcinoma.
- Development of a novel immune-related lncRNA prognostic signature for patients with hepatocellular carcinoma.
- The effect of the number of hepatic inflow occlusion times on the prognosis of ruptured hepatocellular carcinoma patients after hepatectomy.
- Emerging roles and potential clinical applications of long non-coding RNAs in hepatocellular carcinoma.
- Tumor-associated macrophages in liver cancer: From mechanisms to therapy.
- HNRNPC downregulation inhibits IL-6/STAT3-mediated HCC metastasis by decreasing HIF1A expression.
- Cell adhesion molecule BVES functions as a suppressor of tumor cells extrusion in hepatocellular carcinoma metastasis.
- ALKBH5-mediated m6A modification of lincRNA LINC02551 enhances the stability of DDX24 to promote hepatocellular carcinoma growth and metastasis.
- USF2-mediated upregulation of TXNRD1 contributes to hepatocellular carcinoma progression by activating Akt/mTOR signaling.
- Non-coding small nucleolar RNA SNORD17 promotes the progression of hepatocellular carcinoma through a positive feedback loop upon p53 inactivation.
- Small Nucleolar RNAs and Their Comprehensive Biological Functions in Hepatocellular Carcinoma.
- Hsa-microRNA-27b-3p inhibits hepatocellular carcinoma progression by inactivating transforming growth factor-activated kinase-binding protein 3/nuclear factor kappa B signalling.
- Discoidin domain receptor 1 promotes hepatocellular carcinoma progression through modulation of SLC1A5 and the mTORC1 signaling pathway.
- Protein arginine methyltransferase 3 promotes glycolysis and hepatocellular carcinoma growth by enhancing arginine methylation of lactate dehydrogenase A.
- Apparent Diffusion Coefficient as a Noninvasive Biomarker for the Early Response in Hepatocellular Carcinoma After Transcatheter Arterial Chemoembolization Using Drug-eluting Beads.
- Changes in Inflammatory Markers Predict the Prognosis of Resected Hepatocellular Carcinoma with Child-Pugh A.
- Alpha-Fetoprotein+Alkaline Phosphatase (A-A) Score Can Predict the Prognosis of Patients with Ruptured Hepatocellular Carcinoma Underwent Hepatectomy.
- Hepatectomy for ruptured hepatocellular carcinoma classified as Barcelona Clinic Liver Cancer stage 0/A: The optimal treatment.
- Evaluation of contrast-enhanced ultrasound LI-RADS version 2017: application on 271 liver nodules in individuals with non-alcoholic steatohepatitis.
- Identifying potential pharmacological targets and mechanisms of vitamin D for hepatocellular carcinoma and COVID-19.
- Case report: Mycobacterium neoaurum infection during ICI therapy in a hepatocellular carcinoma patient with psoriasis.
- A Novel hepatocellular carcinoma specific hypoxic related signature for predicting prognosis and therapeutic responses.
- Bone metastasis of hepatocellular carcinoma: facts and hopes from clinical and translational perspectives.
- Pan-cancer analysis combined with experimental validation revealed IL4I1 as an immunological and prognostic biomarker.
- Hypothyroidism is a predictive factor of superior antitumour efficacy of programmed death 1 inhibitors in hepatocellular carcinoma.
- Efficacy, safety, and prognostic factors of drug-eluting beads transarterial chemoembolization using CalliSpheres in treating huge hepatocellular carcinoma patients.
- TRIM proteins in hepatocellular carcinoma.
- HGF-mediated elevation of ETV1 facilitates hepatocellular carcinoma metastasis through upregulating PTK2 and c-MET.
- EIF4A3-induced circTOLLIP promotes the progression of hepatocellular carcinoma via the miR-516a-5p/PBX3/EMT pathway.
- T-box transcription factor 19 promotes hepatocellular carcinoma metastasis through upregulating EGFR and RAC1.
- DDR1 promotes hepatocellular carcinoma metastasis through recruiting PSD4 to ARF6.
- DJ-1/FGFR-1 Signaling Pathway Contributes to Sorafenib Resistance in Hepatocellular Carcinoma.
- Comparison of the prognosis of BCLC stage A ruptured hepatocellular carcinoma patients after undergoing transarterial chemoembolization (TACE) or hepatectomy: a propensity score-matched landmark analysis.
- 18[Formula: see text]-Glycyrrhetinic Acid Inhibits TGF-[Formula: see text]-Induced Epithelial-to-Mesenchymal Transition and Metastasis of Hepatocellular Carcinoma by Targeting STAT3.
- Overexpression of BACH1 mediated by IGF2 facilitates hepatocellular carcinoma growth and metastasis via IGF1R and PTK2.
- Postoperative outcomes and recurrence patterns of intermediate-stage hepatocellular carcinoma dictated by the sum of tumor size and number.
- Ultrasound-based artificial intelligence in gastroenterology and hepatology.
- Differentiation of hepatocellular carcinoma from intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma in high-risk patients matched to MR field strength: diagnostic performance of LI-RADS version 2018.
- Oxygen-Challenge Blood Oxygen Level-Dependent Magnetic Resonance Imaging for Evaluation of Early Change of Hepatocellular Carcinoma to Chemoembolization: A Feasibility Study.
- Downregulation of lncRNA SBF2-AS1 inhibits hepatocellular carcinoma proliferation and migration by regulating the miR-361-5p/TGF-β1 signaling pathway.
- Comprehensive analysis of the competing endogenous circRNA-lncRNA-miRNA-mRNA network and identification of a novel potential biomarker for hepatocellular carcinoma.
- SnoRD126 promotes the proliferation of hepatocellular carcinoma cells through transcriptional regulation of FGFR2 activation in combination with hnRNPK.
- Combined identification of ARID1A, CSMD1, and SENP3 as effective prognostic biomarkers for hepatocellular carcinoma.
- Transcriptomic characterization reveals prognostic molecular signatures of sorafenib resistance in hepatocellular carcinoma.
- Comment on "Sub-classification of Microscopic Vascular Invasion in Hepatocellular Carcinoma".
- ASO Author Reflections: Collagen Contents of Liver Tissue Are Significantly Correlated with the Severity of Cirrhosis and Posthepatectomy Liver Failure in Hepatocellular Carcinoma Patients with Child-Pugh Grade A Liver Function.
- Liver Collagen Contents Are Closely Associated with the Severity of Cirrhosis and Posthepatectomy Liver Failure in Patients with Hepatocellular Carcinoma and Child-Pugh Grade A Liver Function.
- TDO2 Was Downregulated in Hepatocellular Carcinoma and Inhibited Cell Proliferation by Upregulating the Expression of p21 and p27.
- LncRNA influence sequential steps of hepatocellular carcinoma metastasis.
- LncRNA NBR2 inhibits tumorigenesis by regulating autophagy in hepatocellular carcinoma.
- Metabolic reprogramming of immune cells: Shaping the tumor microenvironment in hepatocellular carcinoma.
- Diagnostic value of gamma-glutamyl transpeptidase to alkaline phosphatase ratio combined with gamma-glutamyl transpeptidase to aspartate aminotransferase ratio and alanine aminotransferase to aspartate aminotransferase ratio in alpha-fetopr
- ONECUT2 facilitates hepatocellular carcinoma metastasis by transcriptionally upregulating FGF2 and ACLY.
- Circular RNA circUBE2J2 acts as the sponge of microRNA-370-5P to suppress hepatocellular carcinoma progression.
- SLC7A2 deficiency promotes hepatocellular carcinoma progression by enhancing recruitment of myeloid-derived suppressors cells.
- GRAMD4 inhibits tumour metastasis by recruiting the E3 ligase ITCH to target TAK1 for degradation in hepatocellular carcinoma.
- L-EGCG-Mn nanoparticles as a pH-sensitive MRI contrast agent.
- ESR1 mediated circ_0004018 suppresses angiogenesis in hepatocellular carcinoma via recruiting FUS and stabilizing TIMP2 expression.
- Bromodomain-containing protein 9 promotes hepatocellular carcinoma progression via activating the Wnt/β-catenin signaling pathway.
- Exploring the Prognostic Value, Immune Implication and Biological Function of H2AFY Gene in Hepatocellular Carcinoma.
- CTNNB1 Alternation Is a Potential Biomarker for Immunotherapy Prognosis in Patients With Hepatocellular Carcinoma.
- Adjuvant treatment strategy after curative resection for hepatocellular carcinoma.
- IL-1β-Induced Elevation of Solute Carrier Family 7 Member 11 Promotes Hepatocellular Carcinoma Metastasis Through Up-regulating Programmed Death Ligand 1 and Colony-Stimulating Factor 1.
- H19 Promotes HCC Bone Metastasis Through Reducing Osteoprotegerin Expression in a Protein Phosphatase 1 Catalytic Subunit Alpha/p38 Mitogen-Activated Protein Kinase-Dependent Manner and Sponging microRNA 200b-3p.
- HRC promotes anoikis resistance and metastasis by suppressing endoplasmic reticulum stress in hepatocellular carcinoma.
- Comprehensive analysis of partial epithelial mesenchymal transition-related genes in hepatocellular carcinoma.
- Advances in drug development for hepatocellular carcinoma: clinical trials and potential therapeutic targets.
- Long non-coding RNA CCDC183-AS1 acts AS a miR-589-5p sponge to promote the progression of hepatocellular carcinoma through regulating SKP1 expression.
- FOXC1 promotes HCC proliferation and metastasis by Upregulating DNMT3B to induce DNA Hypermethylation of CTH promoter.
- Long noncoding RNA SNHG14 promotes hepatocellular carcinoma progression by regulating miR-876-5p/SSR2 axis.
- TBX3 functions as a tumor suppressor downstream of activated CTNNB1 mutants during hepatocarcinogenesis.
- Identification of MCM family as potential therapeutic and prognostic targets for hepatocellular carcinoma based on bioinformatics and experiments.
- Interference with circRNA DOCK1 inhibits hepatocellular carcinoma cell proliferation, invasion and migration by regulating the miR-654-5p/SMAD2 axis.
- Tumor size may influence the prognosis of solitary hepatocellular carcinoma patients with cirrhosis and without macrovascular invasion after hepatectomy.
- Homeobox B5 promotes metastasis and poor prognosis in Hepatocellular Carcinoma, via FGFR4 and CXCL1 upregulation.
- The 14-3-3σ protein promotes HCC anoikis resistance by inhibiting EGFR degradation and thereby activating the EGFR-dependent ERK1/2 signaling pathway.
- Acute graft-versus-host disease after liver transplantation in a close contact with COVID-19: A case report.
- MR versus CEUS LI-RADS for Distinguishing Hepatocellular Carcinoma from other Hepatic Malignancies in High-Risk Patients.
- Author's Reply: Use of Direct Liver Stiffness Measurement in Evaluating the Severity of Liver Cirrhosis in Patients with Hepatocellular Carcinoma.
Chinese-language papers (not in the count)1
All its trials on ClinicalTrials.gov, any status73
- AI-Guided Surveillance and Curative Salvage of Recurrence After Hepatocellular Carcinoma Resection or Ablation
- Denosumab Strategy for Liver Cancer With Bone Metastases
- Surgery Plus Systemic Therapy for Liver Cancer With Extrahepatic Metastases
- Tislelizumab Combined With Huaier Granule as First-line Treatment for Unresectable Hepatocellular Carcinoma
- AI-Guided First-Line Immunotherapy Selection in Unresectable Hepatocellular Carcinoma
- Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer
- Predictive Value of Minimal Residual Disease for Postoperative Recurrence and Adjuvant PD-1 Inhibitor in HCC
- Multimodal Deep Learning for Postoperative Liver Cancer Risk Stratification and Intervention
- TACE Combined With Tislelizumab, Lenvatinib, and Carvedilol for Unresectable HCC With Cirrhotic Portal Hypertension
- Tauroursodeoxycholic Acid Combined With PD-1/PD-L1 Immunotherapy in Advanced Hepatocellular Carcinoma: A Prospective Study
- Iparomlimab and Tuvonralimab as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With High Risk of Recurrence
- AI-Based Prediction of HCC Recurrence Patterns After Resection (APAR)
- Postoperative Adjuvant Sintilimab in Hepatocellular Carcinoma With Microvascular Invasion
- Circulating Tumor Mitochondrial DNA (ct-mtDNA) As a Biomarker for Hepatocellular Carcinoma Recurrence Surveillance
- Multimodalomics-based Construction of Spatiotemporal Characteristics of Dynamic Liver Cancer Microenvironment to Characterize the Clinical Application of Immune Mechanisms in Liver Cancer
- HAIC, Lenvatinib, and Cadonilimab as Conversion Therapy for Initially Unresectable Hepatocellular Carcinoma
- Ambispective Cohort Study of Precision Medicine for Primary Hepatobiliary Cancer Based on Next-generation Sequencing
- A Multicenter, Prospective Study of Perioperative Finotonlimab Combined With Bevacizumab in Resectable Hepatocellular Carcinoma Patients With High-Risk Factors for Recurrence
- Precision Recurrence Risk Assessment in Early-stage Hepatocellular Carcinoma
- A Study to Evaluate Sintilimab Plus Lenvatinib as Adjuvant Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis (PVTT) After Surgical Resection
- Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma
- Prospective Evaluation of a Locked Risk-Stratified Surveillance Strategy for Extrahepatic Metastasis in Hepatocellular Carcinoma
- PVE/PVL Combined With DEB-TACE in the Treatment of Patients With Large and Unresectable Liver Cancer
- Real-world Study of Efficacy and Safety of ICIs and TKIs Therapy for HCC
- Clinical Study on BIFICO Accelerating Postoperative Liver Function Recovery in Patients With Hepatocellular Carcinoma
- Primary Hepatobiliary Cancer Cohort of Central China
- The Application of Locoregional Therapy Combined With Systemic Therapy in the Perioperative Period of Huge Hepatocellular Carcinoma: A Retrospective Cohort Study
- The Effect of Gut Microbiota on Postoperative Liver Function Recovery in Patients With Hepatocellular Carcinoma
- Circulating Tumor Cell Detection in Hepatocellular Carcinoma
- Icaritin Soft Capsules+TACE+Immunotherapy+Targeted Therapy Versus TACE+Immunotherapy+Targeted Therapy for Unresectable Hepatocellular Carcinoma
- Apatinib Mesylate and Camrelizumab Combined With TACE as Neoadjuvant Therapy for Hepatocellular Carcinoma
- QL1706 As Second-line Treatment in Patients with Advanced Hepatocellular Carcinoma
- Impact of Splenectomy on the Efficacy of Targeted Therapy and Immunotherapy in Unresectable HCC Patients With Cirrhotic Portal Hypertension
- Palliative Hepatectomy Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular Carcinoma
- Precision Adjuvant Therapy After Surgery for Hepatocellular Carcinoma
- A Single-arm Clinical Study of HAIC Combined With Apatinib and Camrelizumab in the Treatment of Unresectable MTM HCC
- Nocardia Rubra Cell Wall Skeleton (N-CWS) Plus HAIC, Lenvatinib and Tislelizumab in Treating Patients With Advanced HCC
- Recurrence Patterns and Cost-Effectiveness of Surgical Approaches in Early-Stage Hepatocellular Carcinoma
- Adjuvant PD-1 Inhibitor for Patients With Early-stage Hepatocellular Carcinoma Following Microwave Ablation
- Hyperbaric Oxygen Therapy Combined Camrelizumab in Patients With Advanced/Metastatic Hepatocellular Carcinoma
- ML Models for Predicting Postoperative Peritoneal Metastasis After Hepatocellular Carcinoma Rupture
- Surgical Stages of Liver Cirrhosis In Patients With Hepatocellular Carcinoma
- Evaluate the Treatment With Sintilimab Injection Plus Endostar in Hepatocellular Carcinoma
- Postoperative Adjuvant Therapy of HCC Based on PD-1
- Intra-Tumoral Vascular Growth Patterns is a Robust Indicator of Adjuvant Therapy Following Liver Resection in HCC
- Postoperative Adjuvant Immunotherapy for Hepatocellular Carcinoma: Risk Factor Analysis and Prognostic Modelling
- Comparing the Prognosis of Patients With HCC and PVTT Treated With Surgery Versus Locoregional Therapy.
- Anatomy-based Resection or Margin-based Resection for Hepatocellular Carcinoma
- A Long-term Survival Analysis of Different Surgical Method in Early Hepatocellular Carcinoma
- Infrahepatic Inferior Vena Cava Clamping Versus Selective Hepatic Vascular Exclusion Involving the Portal Triad Clamping
- Rapid Ligating the Corresponding Inflow and Outflow Vessels Without Hilus Dissection During Hepatectomy
- cfDNA Methylation for Liver Cancer Recurrence Detection
- ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
- Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
- Phase 2 Study of WGI-0301 for Advanced HCC
- A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
- CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical Resection
- A Phase 2, Open-Label Study of ABSK-011 Combined Atezolizumab or SOC in HCC Patients
- A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)
- Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated Primary Liver Cancer
- A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/Bev
- Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)
- Efficacy and Safety of Lenvatinib as a Conversion Therapy for HCC
- Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC
- A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC
- A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma
- Efficacy and Safety of Lenvatinib as an Adjuvant Therapy for Hepatocellular Carcinoma
- Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394)
- The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects
- the Efficacy and Safety of Ginsenoside Rg3 Capsule in Prevention of Postoperative Recurrence of Hepatocellular Carcinoma
- Huaier Granule for Prevention of Disease Progression of Hepatocarcinoma After Non-radical Hepatectomy
- Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma After Radical Hepatectomy
- Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)
Cancer
Stomach cancer
胃癌Led 45 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.5%.
5 hospitals in Wuhan for stomach cancer218 hospitals in China for stomach cancer
Open trials with this hospital 12
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingMulticenter Observational Study of Multimodal AI for Upper GI Mesenchymal Tumor Diagnosis
- Phase
- Not given
- Started
- 2025-07
- Registry
- NCT07078136
Age 18 years to Not stated (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingProximal Gastrectomy vs Total Gastrectomy in Locally Advanced Upper Gastric Cancer After Neoadjuvant Therapy
- Phase
- N/A
- Started
- 2024-03
- Registry
- NCT06597227
Age 18 years to 75 years (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingClinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Patients With Taxans-resistant Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Gastric Cancer, Esophageal Carcinoma, or Breast Cancer
- Phase
- Phase 2
- Started
- 2023-11
- Registry
- NCT06199895
Age 18 years to Not stated (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingExploratory Study of Precise Therapy for Advanced Tumor Patients With Malignant Hydrothorax or Ascites by Using PTC Drug Sensitivity Testing
- Phase
- Not given
- Started
- 2023-08
- Registry
- NCT06413212
Age 18 years to Not stated (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingClinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
- Phase
- Phase 3
- Started
- 2026-04
- Registry
- NCT07385703
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 62 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Changzhou, Chengde, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Nanchang, Nanchong, Nanjing, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xuzhou, Yangzhou, Zhengzhou
- RecruitingRadical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy
- Phase
- Phase 3
- Started
- 2026-12
- Registry
- NCT07789184
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 25 listed hospitals as study sitesBeijing, Changchun, Chongqing, Dalian, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Qingdao, Shanghai, Tianjin, Urumqi, Wuhan, Xi'an
- RecruitingClinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric Cancer
- Phase
- N/A
- Started
- 2024-09
- Registry
- NCT06128252
Age 18 years to 75 years (registered criteria)
Led by Tangdu Hospital; 11 listed hospitals as study sitesChongqing, Nanjing, Shanghai, Shenyang, Urumqi, Wuhan, Xi'an
- RecruitingA Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2024-07
- Registry
- NCT06427941
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Hefei, Nanchang, Nanning, Shijiazhuang, Wenzhou, Wuhan, Xuzhou
- RecruitingA Phase 2 Clinical Study of ABSK061 and ABSK043
- Phase
- Phase 2
- Started
- 2024-11
- Registry
- NCT06632262
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesChengdu, Guiyang, Hangzhou, Harbin, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wuhan, Xiamen, Xiangyang, Xuzhou, Zhengzhou
- RecruitingTislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ Adenocarcinoma
- Phase
- Phase 2
- Started
- 2023-03
- Registry
- NCT05687357
Age 18 years to 75 years (registered criteria)
Led by Nanjing Drum Tower Hospital; 2 listed hospitals as study sitesNanjing, Taiyuan, Wuhan
- RecruitingComparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma
- Phase
- Phase 3
- Started
- 2023-04
- Registry
- NCT05918094
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer Center; 6 listed hospitals as study sitesChengdu, Guangzhou, Harbin, Nanchang, Shanghai, Wuhan, Zhengzhou
- Not yet recruitingA Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers
- Phase
- Phase 2
- Started
- 2025-11
- Registry
- NCT07233850
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteWuhan
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led45
- Cancer cell-extrinsic STING shapes immune-active microenvironment and predicts clinical outcome in gastric cancer.
- Effects of Thymidine Phosphorylase and Sine Oculis Homeobox Homologue 1 on the Prognosis and Immune Microenvironment of Gastric Cancer.
- Exploring the effect of capsaicin on gene expression and chemotherapy sensitization in gastric cancer cells.
- The circRNA circSCAF8 promotes tumor growth and metastasis of gastric cancer via miR-1293/TIMP1signaling.
- Unveiling lymphocyte dynamics: Navigating postoperative immune landscapes in gastric cancer patients undergoing laparoscopic D2 gastrectomy.
- Prospective multicenter validation of a machine learning model for predicting anastomotic leakage in patients with gastric adenocarcinoma undergoing total or proximal gastrectomy.
- Survival benefit from adjuvant chemoradiotherapy in local advanced gastric cancer without accurate D2 confirmation: a real-world retrospective study (TJ-ARK01).
- Machine learning-based prediction of duodenal stump leakage following laparoscopic gastrectomy for gastric cancer.
- Multi-center phase II study of nab-paclitaxel plus camrelizumab versus nab-paclitaxel alone as second-line treatment for advanced gastric cancer.
- Prophylactic antibiotic use is associated with better clinical outcomes in gastric cancer patients receiving immunotherapy.
- A Novel Nomogram to Predict Resectable Gastric Cancer Based on Preoperative Circulating Tumor Cell.
- Amino acid metabolism-related genes as potential biomarkers and the role of MATN3 in stomach adenocarcinoma: A bioinformatics, mendelian randomization and experimental validation study.
- Role of AT-rich interaction domain 1A in gastric cancer immunotherapy: Preclinical and clinical perspectives.
- Identification of histopathological classification and establishment of prognostic indicators of gastric adenocarcinoma based on deep learning algorithm.
- OCTA-based research on changes of retinal microcirculation in digestive tract malignancy.
- Sensitivity and specificity of folate receptor α-positive circulating tumour cells in gastric cancer.
- The number of mesogastria containing metastatic lymph nodes predicts gastric cancer prognosis.
- Author response to: Comment on: Randomized clinical trial on D2 lymphadenectomy versus D2 lymphadenectomy plus complete mesogastric excision in patients undergoing gastrectomy for cancer (DCGC01 study).
- Author response to: Comment on: Randomized clinical trial on D2 lymphadenectomy versus D2 lymphadenectomy plus complete mesogastric excision in patients undergoing gastrectomy for cancer (DCGC01 study).
- Randomized clinical trial on D2 lymphadenectomy versus D2 lymphadenectomy plus complete mesogastric excision in patients undergoing gastrectomy for cancer (DCGC01 study).
- PWSC: a novel clustering method based on polynomial weight-adjusted sparse clustering for sparse biomedical data and its application in cancer subtyping.
- The role of lncRNA SNHG14 in gastric cancer: enhancing tumor cell proliferation and migration, and mechanisms of CDH2 expression.
- Determination of an Appropriate Endoscopic Monitoring Interval for Patients with Gastric Precancerous Conditions in China.
- Bacterial infection and microbiota in carcinogenesis and tumor development.
- Revalidation of the ATTRACTION-4 study in a real-world setting: a multicenter, retrospective propensity score matching study in China.
- Short-term prognostic role of peripheral lymphocyte subsets in patients with gastric cancer.
- MKL-1 suppresses ferroptosis by activating system Xc- and increasing glutathione synthesis.
- Relationship between endoscopic gastric abnormalities and colorectal polyps: a cross-sectional study based on 33439 Chinese patients.
- Pan-HER Tyrosine Kinase Inhibitor Pyrotinib Enhances Radiosensitivity via ERK1/2 Pathway in HER2-Positive Gastric Cancer.
- Collagen type V alpha 2 promotes the development of gastric cancer via M2 macrophage polarization.
- Prospective Comparison of Oral Contrast-Enhanced Transabdominal Ultrasound Imaging With Contrast-Enhanced Computed Tomography in Pre-operative Tumor Staging of Gastric Cancer.
- Combination of berberine and low glucose inhibits gastric cancer through the PP2A/GSK3β/MCL-1 signaling pathway.
- Epstein-Barr Virus is Associated with Gastric Cancer Precursor: Atrophic Gastritis.
- Clinical outcomes of endoscopic treatment for gastric gastrointestinal stromal tumors: a single-center study of 240 cases in China.
- Short-term outcomes of D2 lymphadenectomy plus complete mesogastric excision for gastric cancer: a propensity score matching analysis.
- Clinico-pathologic determinants of non-e-curative outcome following en-bloc endoscopic submucosal dissection in patients with early gastric neoplasia.
- Bioinformatics analysis identifies COL1A1, THBS2 and SPP1 as potential predictors of patient prognosis and immunotherapy response in gastric cancer.
- Complete mesogastric excision for locally advanced gastric cancer: short-term outcomes of a randomized clinical trial.
- Clinical Features of Oxaliplatin-induced Hypersensitivity Reactions in Chinese Patients: A Retrospective Multicenter Analysis.
- Apatinib exhibits synergistic effect with pyrotinib and reverses acquired pyrotinib resistance in HER2-positive gastric cancer via stem cell factor/c-kit signaling and its downstream pathways.
- Bibliometric Evaluation of Publications (2000-2020) on the Prognosis of Gastric Cancer.
- PARP inhibitors in gastric cancer: beacon of hope.
- Gastrin-17 induces gastric cancer cell epithelial-mesenchymal transition via the Wnt/β-catenin signaling pathway.
- In Gastric Cancer Patients Receiving Neoadjuvant Chemotherapy Systemic Inflammation Response Index is a Useful Prognostic Indicator.
- Intussusception after reconstruction following gastrectomy for gastric cancer.
Chinese-language papers (not in the count)6
- [The impact of neoadjuvant immunotherapy on postoperative complications and short-term efficacy in patients with advanced gastric cancer].
- [Immunotherapy: progress and challenges of a revolutionary treatment for gastric cancer].
- [Attach importance to functional evaluation after gastric-preserving surgery].
- [Rethinking the scope of lymphadenectomy after neoadjuvant immunotherapy for locally advanced gastric cancer].
- [Development of membrane anatomy theory in gastric cancer surgery].
- [Demonstration and significance on proximal segment of dorsal mesogastrium].
All its trials on ClinicalTrials.gov, any status40
- Multicenter Observational Study of Multimodal AI for Upper GI Mesenchymal Tumor Diagnosis
- Proximal Gastrectomy vs Total Gastrectomy in Locally Advanced Upper Gastric Cancer After Neoadjuvant Therapy
- Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Patients With Taxans-resistant Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Gastric Cancer, Esophageal Carcinoma, or Breast Cancer
- Exploratory Study of Precise Therapy for Advanced Tumor Patients With Malignant Hydrothorax or Ascites by Using PTC Drug Sensitivity Testing
- Effect of Gastrectomy on Gut Microbiome and Cognitive Function
- Comparison of pCLE and EB in Gastric Lesion Diagnosis
- The Combination of Adebrelimab, Apatinib, and Lrinotecan Liposome for Second-line Treatment of Advanced Gastric Cancer
- Validation of a Model for Predicting Anastomotic Leakage
- Nab-paclitaxel Plus PD-1 Inhibitor Versus Nab-paclitaxel As Second-line Treatment in Advanced Gastric Cancer
- The Number of Mesogastria Containing Metastatic Lymph Nodes Predicts Gastric Cancer Prognosis
- Albumin-bound Paclitaxel Plus S-1 Versus SOX as First-line Treatment in Advanced or Recurrent Gastric Adenocarcinoma
- Phase III Trial of Adjuvant Chemo-radiotherapy After D2 Surgery of Gastric Cancer
- Study on Laparoscopic D2 Lymphadenectomy Plus Complete Mesogastrium Excision(D2+CME)for Advanced Gastric Cancer
- The First-line Combined Chemotherapy for Advanced Gastric Cancer: A Prospective Observational Clinical Study
- Postoperative Sequence Chemoradiotherapy Compared With Chemotherapy Alone for Advanced Gastric Cancer
- Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy
- Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
- A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers
- A Phase 2 Clinical Study of ABSK061 and ABSK043
- Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric Cancer
- A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
- Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma
- Tislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ Adenocarcinoma
- Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
- A Study of Treatment Patterns in HER2-positive Unresectable and Advanced Gastric/ Gastroesophageal Junction Cancer in China
- Plasma Metabolic Biomarkers for Gastric Cancer Diagnosis
- Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma
- Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
- Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.
- Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs
- A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression
- Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901
- Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)
- Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection
- A Study of Gentuximab + Paclitaxel in Patients With Advanced Gastric or Gastroesophageal Junction Cancer
- BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Carcinoma
- A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer
- The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC
- Study of Anlotinib in Patients With Gastric Cancer(ALTER0503)
- A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer
Cancer
Hepatoblastoma
肝母细胞瘤Led no English-language PubMed papers on hepatoblastoma in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
5 hospitals in Wuhan for hepatoblastoma88 hospitals in China for hepatoblastoma
No open trial on hepatoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Cancer
Retinoblastoma
视网膜母细胞瘤Led 1 of the 301 English-language PubMed papers on retinoblastoma with an author in mainland China, 2021–2025: 0.3%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
18 hospitals in Wuhan for retinoblastoma196 hospitals in China for retinoblastoma
No open trial on retinoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led1
Cancer
Chordoma
脊索瘤Led 1 of the 105 English-language PubMed papers on chordoma with an author in mainland China, 2021–2025: 0.9%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Wuhan for chordoma88 hospitals in China for chordoma
No open trial on chordoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Cancer
Osteosarcoma
骨肉瘤Led 12 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.5%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
31 hospitals in Wuhan for osteosarcoma742 hospitals in China for osteosarcoma
No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led12
- Construction and clinical validation of a machine-learning-based consensus prognostic signature (MLPS) for osteosarcoma via multi-cohort data integration.
- OTULIN confers cisplatin resistance in osteosarcoma by mediating GPX4 protein homeostasis to evade the mitochondrial apoptotic pathway.
- EphA2-specific microvesicles derived from tumor cells facilitate the targeted delivery of chemotherapeutic drugs for osteosarcoma therapy.
- Cancer-Erythrocyte Membrane-Mimicking Fe3O4 Nanoparticles and DHJS for Ferroptosis/Immunotherapy Synergism in Tumors.
- Functional heterogeneity of MCT1 and MCT4 in metabolic reprogramming affects osteosarcoma growth and metastasis.
- P2RX7 promotes osteosarcoma progression and glucose metabolism by enhancing c-Myc stabilization.
- Predictive value of preoperative platelet-to-albumin ratio and apolipoprotein B-to-apolipoprotein A1 ratio for osteosarcoma in children and adolescents: a retrospective study of 118 cases.
- ALKBH5 regulates STAT3 activity to affect the proliferation and tumorigenicity of osteosarcoma via an m6A-YTHDF2-dependent manner.
- Infiltration of LPAR5+ macrophages in osteosarcoma tumor microenvironment predicts better outcomes.
- Preoperative prognostic nutritional index and systemic immune-inflammation index predict survival outcomes in osteosarcoma: A comparison between young and elderly patients.
- TRAIP modulates the IGFBP3/AKT pathway to enhance the invasion and proliferation of osteosarcoma by promoting KANK1 degradation.
- Comprehensive Analysis of Key mRNAs and lncRNAs in Osteosarcoma Response to Preoperative Chemotherapy with Prognostic Values.
Earlier papers (2016–2020)14
- Specific Small-Molecule NIR-II Fluorescence Imaging of Osteosarcoma and Lung Metastasis.
- Key genes with prognostic values in suppression of osteosarcoma metastasis using comprehensive analysis.
- HOTAIR Promotes Cisplatin Resistance of Osteosarcoma Cells by Regulating Cell Proliferation, Invasion, and Apoptosis via miR-106a-5p/STAT3 Axis.
- Expression of CXCR4 and MMP-2 is associated with poor prognosis in patients with osteosarcoma.
- Knockdown of STIP1 inhibits the invasion of CD133‑positive cancer stem‑like cells of the osteosarcoma MG63 cell line via the PI3K/Akt and ERK1/2 pathways.
- Highly-expressed P2X7 receptor promotes growth and metastasis of human HOS/MNNG osteosarcoma cells via PI3K/Akt/GSK3β/β-catenin and mTOR/HIF1α/VEGF signaling.
- Survival analysis of patients with metastatic osteosarcoma: a Surveillance, Epidemiology, and End Results population-based study.
- Integrative analyses of key genes and regulatory elements in fluoride-affected osteosarcoma.
- Matrix stiffness regulates epithelial-mesenchymal transition via cytoskeletal remodeling and MRTF-A translocation in osteosarcoma cells.
- Clinical Features and Long-Term Outcome of Primary Intracranial Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumors: 14 Cases From a Single Institution.
- Inhibition of LCMR1 and ATG12 by demethylation-activated miR-570-3p is involved in the anti-metastasis effects of metformin on human osteosarcoma.
- MMP-1 Over-expression Promotes Malignancy and Stem-Like Properties of Human Osteosarcoma MG-63 Cells In Vitro.
- Flavonoids Active Against Osteosarcoma: A Review of the Molecular Mechanisms Involved.
- Meningeal Ewing Sarcoma/Peripheral PNET: Clinicopathological, Immunohistochemical and FISH study of four cases.
Cancer
Gastrointestinal stromal tumour
胃肠道间质瘤Led 3 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 0.6%.
- Open trials as a site
- 0
- led by another institution
9 hospitals in Wuhan for gastrointestinal stromal tumour261 hospitals in China for gastrointestinal stromal tumour
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingMulticenter Observational Study of Multimodal AI for Upper GI Mesenchymal Tumor Diagnosis
- Phase
- Not given
- Started
- 2025-07
- Registry
- NCT07078136
Age 18 years to Not stated (registered criteria)
Led by Tongji HospitalWuhan
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led3
- MicroRNA-409-5p Inhibits GIST Tumorigenesis and Improves Imatinib Resistance by Targeting KDM4D Expression.
- Clinical outcomes of endoscopic treatment for gastric gastrointestinal stromal tumors: a single-center study of 240 cases in China.
- Current knowledge of primary prostatic extra-gastrointestinal stromal tumor: a case report and review of the literature.
Earlier papers (2016–2020)8
- Assessment of tumor heterogeneity: Differentiation of periampullary neoplasms based on CT whole-lesion histogram analysis.
- Tumor heterogeneity in gastrointestinal stromal tumors of the small bowel: volumetric CT texture analysis as a potential biomarker for risk stratification.
- miR-148b-3p functions as a tumor suppressor in GISTs by directly targeting KIT.
- Histone demethylase KDM4D promotes gastrointestinal stromal tumor progression through HIF1β/VEGFA signalling.
- CD117 is not always positive in infantile gastrointestinal stromal tumor.
- Imbedding pancreaticojejunostomy used in pure laparoscopic pancreaticoduodenectomy for nondilated pancreatic duct.
- KIT over-expression by p55PIK-PI3K leads to Imatinib-resistance in patients with gastrointestinal stromal tumors.
- [Comparison of the clinical efficacy of laparoscopic wedge resection and open wedge resection for the treatment of gastrointestinal stromal tumor].
Cancer
Neuroblastoma
神经母细胞瘤Led 8 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.7%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
11 hospitals in Wuhan for neuroblastoma352 hospitals in China for neuroblastoma
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingAPG-115 Alone or in Combination With APG-2575 in Recurrent or Refractory Neuroblastoma or Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2023-02
- Registry
- NCT05701306
Age 5 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesGuangzhou, Tianjin, Wuhan
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led8
- Integrated bulk and single-cell RNA sequencing reveals a cuproptosis-related LncRNA prognostic signature in neuroblastoma.
- Identification of Crucial Genes Associated With MYCN-Driven Neuroblastoma Based on Single-Cell Analysis and Machine Learning.
- Distal-less homeobox 5 transactivated by MYCN contributes to progression of neuroblastoma through AKT signaling pathway.
- Leveraging small voxel with optimal acquisition time for [18F]mFBG total-body PET/CT imaging in pediatric patients with neuroblastoma: a preliminary study.
- Prediction of neuroblastoma prognosis with a novel T-cell exhaustion-related gene signature.
- MicroRNA-218-5p-Ddx41 axis restrains microglia-mediated neuroinflammation through downregulating type I interferon response in a mouse model of Parkinson's disease.
- NTRK1-mediated protection against manganese-induced neurotoxicity and cell apoptosis via IGF2 in SH-SY5Y cells.
- Transcriptomics reveals the effects of NTRK1 on endoplasmic reticulum stress response-associated genes in human neuronal cell lines.
Earlier papers (2016–2020)5
- Identification of prognostic long noncoding RNAs associated with spontaneous regression of neuroblastoma.
- NBPF1 independently determine the risk stratification and prognosis of patients with neuroblastoma.
- Combined analysis of RNA-sequence and microarray data reveals effective metabolism-based prognostic signature for neuroblastoma.
- Analytical validation and clinical application of urinary vanillylmandelic acid and homovanillic acid by LC-MS/MS for diagnosis of neuroblastoma.
- Comparison of diagnosing and staging accuracy of PET (CT) and MIBG on patients with neuroblastoma: Systemic review and meta-analysis.
All its trials on ClinicalTrials.gov, any status1
Cancer
Ewing sarcoma
尤文肉瘤Led no English-language PubMed papers on Ewing sarcoma in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
6 hospitals in Wuhan for Ewing sarcoma139 hospitals in China for Ewing sarcoma
No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Blood disorders
Multiple myeloma
多发性骨髓瘤Led 19 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 1.1%.
3 hospitals in Wuhan for multiple myeloma178 hospitals in China for multiple myeloma
Open trials with this hospital 15
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Study of ESO-T01 in Treating Relapsed/ Refractory Multiple Myeloma
- Phase
- Early phase 1
- Started
- 2025-01
- Registry
- NCT06791681
Age 18 years to Not stated (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingA Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
- Phase
- Phase 1
- Started
- 2022-03
- Registry
- NCT05219721
Age 18 years to 75 years (registered criteria)
Led by Tongji HospitalWuhan
- Not yet recruitingA Clinical Study Evaluating the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Have Received Three or More Lines of Treatment
- Phase
- N/A
- Started
- 2026-02
- Registry
- NCT07376720
Age 18 years to 78 years (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingA Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- Phase
- Phase 3
- Started
- 2026-02
- Registry
- NCT07258511
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Chengdu, Hangzhou, Nanjing, Nanning, Wenzhou, Wuhan, Xi'an
- RecruitingA Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
- Phase
- Phase 1
- Started
- 2026-05
- Registry
- NCT07477587
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 46 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Weifang, Wenzhou, Wuhan, Wuxi, Xiamen, Xuzhou, Zhengzhou
- RecruitingA Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Phase
- Phase 3
- Started
- 2026-05
- Registry
- NCT07518186
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changchun, Chengdu, Hangzhou, Nanchang, Nanjing, Shenzhen, Tianjin, Wenzhou, Wuhan, Xi'an
- RecruitingCevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
- Phase
- Phase 3
- Started
- 2026-06
- Registry
- NCT07555938
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesGuangzhou, Hangzhou, Jinan, Kunming, Nanjing, Qingdao, Shanghai, Suzhou, Tianjin, Wenzhou, Wuhan
- RecruitingIsatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients
- Phase
- Not given
- Started
- 2026-06
- Registry
- NCT07663253
Age 18 years to Not stated (registered criteria)
Led by Zhongshan Hospital, Fudan University; 9 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Kunming, Nanning, Nantong, Shanghai, Wuhan, Xi'an, Zhengzhou
- RecruitingA Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
- Phase
- Phase 1/Phase 2
- Started
- 2024-07
- Registry
- NCT06083207
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Nanjing, Nanning, Shanghai, Suzhou, Tianjin, Wuhan, Xi'an, Xuzhou
- RecruitingLong-term Follow-up Registry Study of Equecabtagene Autoleucel Injection
- Phase
- Not given
- Started
- 2024-12
- Registry
- NCT07028970
Age not stated (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Tianjin, Wuhan, Zhengzhou
- RecruitingPhase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
- Phase
- Phase 3
- Started
- 2022-09
- Registry
- NCT05243797
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Changchun, Hangzhou, Jinan, Shanghai, Shenyang, Tianjin, Wenzhou, Wuhan, Zhengzhou
- RecruitingA Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- Phase
- Phase 3
- Started
- 2022-10
- Registry
- NCT05552222
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shenzhen, Tianjin, Wenzhou, Wuhan, Xi'an, Xiamen, Zhengzhou
- RecruitingA Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
- Phase
- Phase 3
- Started
- 2022-11
- Registry
- NCT05623020
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changchun, Fuzhou, Guangzhou, Hangzhou, Nanjing, Shanghai, Suzhou, Tianjin, Wenzhou, Wuhan
- RecruitingA Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
- Phase
- Phase 3
- Started
- 2021-10
- Registry
- NCT05020236
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Changchun, Chongqing, Fuzhou, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Shenzhen, Shijiazhuang, Tianjin, Wenzhou, Wuhan, Xuzhou, Zhengzhou
- Not yet recruitingA Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Multiple Myeloma(LB2505-0001)
- Phase
- Early phase 1
- Started
- 2026-01
- Registry
- NCT07399444
Age 18 years to Not stated (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 4 listed hospitals as study sitesNanchang, Tianjin, Wuhan, Xuzhou, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led19
- Application of GPRC5D Targeting Therapy in Relapsed Refractory Multiple Myeloma.
- A successful haploidentical transplantation without conditioning regimen for a relapsed/refractory multiple myeloma patient after chimeric antigen receptor T-cell therapy.
- Key predictors of long-term outcomes in BCMA-targeted CAR-T therapy for relapsed/refractory multiple myeloma.
- Long-term safety and efficacy of the fully human CAR-T therapy CT103A in relapsed/refractory multiple myeloma.
- B cell lineage reconstitution underlies CAR-T cell therapeutic efficacy in patients with refractory myasthenia gravis.
- Single-cell analysis of refractory anti-SRP necrotizing myopathy treated with anti-BCMA CAR-T cell therapy.
- The exploration of B cell maturation antigen expression in plasma cell dyscrasias beyond multiple myeloma.
- A novel two-step administration of XPO-1 inhibitor may enhance the effect of anti-BCMA CAR-T in relapsed/refractory extramedullary multiple myeloma.
- Coexistence of primary mediastinal MALT lymphoma and multiple myeloma like POEMS syndrome: A case report and literature review.
- Recovery-model: A model for CAR T-cell-related thrombocytopenia in relapsed/refractory multiple myeloma.
- Rare Distribution of Sclerotic Bony Lesions in Multiple Myeloma: A Case Report.
- Anti-BCMA CAR-T cells therapy for a patient with extremely high membrane BCMA expression: a case report.
- Refractory postherpetic neuralgia in a multiple myeloma patient with lenalidomide maintenance therapy: a case report.
- A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma.
- Viral infection/reactivation during long-term follow-up in multiple myeloma patients with anti-BCMA CAR therapy.
- A phase I study of anti-BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia.
- Anti-BCMA CAR-T Cell Therapy in Relapsed or Refractory Multiple Myeloma Patients with Impaired Renal Function.
- Anti-BCMA CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease: A Single Center Analysis of Two Clinical Trials.
- Long event-free survival after anti-BCMA CAR-T cell treatment for relapsed and refractory multiple myeloma patients: Two case reports.
Chinese-language papers (not in the count)1
All its trials on ClinicalTrials.gov, any status30
- A Clinical Study Evaluating the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Have Received Three or More Lines of Treatment
- A Study of ESO-T01 in Treating Relapsed/ Refractory Multiple Myeloma
- A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
- A Study of a Fully Human BCMA-targeting CAR (CT103A) Combined With Selinexor in Patients With Relapsed/Refractory Extramedullary Multiple Myeloma
- Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI346#CIBI346Y002#
- Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
- A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients
- A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Multiple Myeloma(LB2505-0001)
- A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
- Long-term Follow-up Registry Study of Equecabtagene Autoleucel Injection
- A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
- A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
- Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
- A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
- A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Refractory Multiple Myeloma
- A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
- A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)
- Umbilical Cord Derived Mesenchymal Stem Cells for Treatment-induced Myelosuppression in Hematologic Malignancies
- the Safety and Efficacy of SENL103 Autologous T Cell Injection
- A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
- A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
- A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory Myeloma
- A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma (FUMANBA-1)
- Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT)
- A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)
- A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma
- Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy
Blood disorders
B-cell acute lymphoblastic leukaemia
B 细胞急性淋巴细胞白血病Led 7 of the 225 English-language PubMed papers on B-cell acute lymphoblastic leukaemia with an author in mainland China, 2021–2025: 3.1%.
3 hospitals in Wuhan for B-cell acute lymphoblastic leukaemia90 hospitals in China for B-cell acute lymphoblastic leukaemia
Open trials with this hospital 7
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingJY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia
- Phase
- N/A
- Started
- 2025-01
- Registry
- NCT06689917
Age 18 years to 75 years (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingNewly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol
- Phase
- Phase 2/Phase 3
- Started
- 2025-01
- Registry
- NCT06764238
Age 1 month to 18 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 24 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hefei, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenzhen, Suzhou, Tianjin, Wuhan, Xi'an
- RecruitingNewly-diagnosed Low Risk Pediatric B-cell ALL Protocol
- Phase
- Phase 2/Phase 3
- Started
- 2025-03
- Registry
- NCT06882057
Age 1 year to 18 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 23 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hefei, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Suzhou, Tianjin, Wuhan, Xi'an
- RecruitingNewly-diagnosed Pediatric Ph-positive B-ALL Protocol
- Phase
- Phase 3
- Started
- 2025-03
- Registry
- NCT07152041
Age 1 month to 18 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 20 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Jinan, Nanchang, Nanjing, Qingdao, Shanghai, Shenzhen, Suzhou, Tianjin, Wuhan
- RecruitingA Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia.
- Phase
- Phase 1
- Started
- 2024-09
- Registry
- NCT06927466
Age 3 years to 25 years (registered criteria)
Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesBeijing, Nanchang, Shanghai, Suzhou, Wuhan, Xuzhou
- RecruitingA Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents
- Phase
- Phase 2
- Started
- 2022-01
- Registry
- NCT05334823
Age 3 years to 21 years (registered criteria)
Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Hangzhou, Nanchang, Nanjing, Shenzhen, Suzhou, Tianjin, Wuhan, Zhengzhou
- RecruitingA Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)
- Phase
- Phase 1/Phase 2
- Started
- 2022-11
- Registry
- NCT05579132
Age 2 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesChengdu, Chongqing, Guangzhou, Hangzhou, Tianjin, Wuhan, Xuzhou, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led7
- Blinatumomab in pediatric B-acute lymphoblastic leukemia.
- Efficacy and safety comparison of CAR-T and blinatumomab immunotherapy as bridge-to-transplant strategies in relapsed/refractory B cell acute lymphoblastic leukemia.
- FISH combined with RT-PCR facilitates classification of Chinese adult patients with B-other ALL through improved identification of ZNF384 rearrangement.
- Short-Course Blinatumomab Treatment as a Bridge to Further Salvage Therapy for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia: A Retrospective Single-Center Study.
- MIP3α as an early prognostic predictor for patients with B-cell malignancies receiving CD19/CD22-redirected CAR-T cell cocktail therapy.
- Functional diversification and dynamics of CAR-T cells in patients with B-ALL.
- Upregulation of CD22 by Chidamide promotes CAR T cells functionality.
Chinese-language papers (not in the count)1
All its trials on ClinicalTrials.gov, any status10
- JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia
- Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol
- Newly-diagnosed Pediatric Ph-positive B-ALL Protocol
- Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol
- A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia.
- A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents
- A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)
- Phase I Study of pCAR-19B in the Treatment of Adult CD19-positive Relapsed/Refractory B-ALL
- Phase I Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents
- Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)
Blood disorders
Aplastic anaemia
再生障碍性贫血Led 8 of the 412 English-language PubMed papers on aplastic anaemia with an author in mainland China, 2021–2025: 1.9%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
4 hospitals in Wuhan for aplastic anaemia63 hospitals in China for aplastic anaemia
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- Not yet recruitingClinical Study on the Preservation of Ovarian Function in Patients With Aplastic Anemia Following Allogeneic Hematopoietic Stem Cell Transplantation Using Goserelin
- Phase
- N/A
- Started
- 2026-05
- Registry
- NCT07552506
Age 14 years to 50 years; women only (registered criteria)
Led by Union Hospital; 3 listed hospitals as study sitesHangzhou, Wuhan, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led8
- Alemtuzumab for haematological malignancies.
- Parvovirus B19-induced aplastic anemia following mechanical valve replacement.
- Comparison of Haploidentical-Hematopoietic Stem Cell Transplantation Using Modified Post-Transplantation Cyclophosphamide and Eltrombopag Combined With Immunosuppression for the Treatment of Severe Aplastic Anemia.
- Recombinant Human Thrombopoietin Promotes Platelet Engraftment in Severe Aplastic Anemia Patients Following Treatment With Haploid Hematopoietic Stem Cell Transplantation using Modified Post-Transplantation Cyclophosphamide.
- An atypical patient with bone marrow failure syndrome-2 without microcephaly and learning disability in a Chinese family.
- Frontline Therapy Options for Adults With Newly Diagnosed Severe Aplastic Anemia: Intensive immunosuppressive Therapy Plus Eltrombopag or Matched Sibling Donor Hematopoietic Stem Cell Transplantation?
- Comparisons of Modified Post-Transplantation Cyclophosphamide and Granulocyte Colony-Stimulating Factor/Antithymocyte Globulin Regimens for Haploidentical Stem Cell Transplantation in Patients with Aplastic Anemia.
- Haploidentical Transplantation with Modified Post-transplantation Cyclophosphamide for Patients with Primary Aplastic Anemia: A Multicenter Experience.
Chinese-language papers (not in the count)1
All its trials on ClinicalTrials.gov, any status1
Blood disorders
Haemophagocytic lymphohistiocytosis
噬血细胞性淋巴组织细胞增生症Led 20 of the 399 English-language PubMed papers on haemophagocytic lymphohistiocytosis with an author in mainland China, 2021–2025: 5.0%.
- Open trials as a site
- 0
- led by another institution
2 hospitals in Wuhan for haemophagocytic lymphohistiocytosis66 hospitals in China for haemophagocytic lymphohistiocytosis
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingSurveillance and Tracking the Outcomes of Chronic Latent EBV Infection
- Phase
- Not given
- Started
- 2019-07
- Registry
- NCT03491605
Age not stated (registered criteria)
Led by Tongji HospitalWuhan
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led20
- A case of cirrhosis concurrent with NK/T-Cell lymphoma and hemophagocytic lymphohistiocytosis: a clinical report and literature review.
- The lncRNA LINC02446 promotes tumor progression and HLH occurrence by regulating the expression of KLRs and IL-10 in EBV-NK-LPDs.
- UNC13D c.2588G>A Nucleotide Variant Impairs NK-Cell Cytotoxicity in Adult-Onset EBV-Associated Hemophagocytic Lymphohistiocytosis: A Pedigree Study.
- Unveiling fatal risk factors: Predicting hemophagocytic lymphohistiocytosis in SFTS patients.
- Deep insight into cytokine storm: from pathogenesis to treatment.
- Immune profiling and prognosis implications in severe fever with thrombocytopenia syndrome with and without hemophagocytic lymphohistiocytosis.
- Comprehensive evaluation of immune dysregulation in secondary hemophagocytic lymphohistiocytosis.
- IFN-α induced systemic lupus erythematosus complicated with hemophagocytic lymphohistiocytosis: a case report and literature review.
- The signature and predictive value of immune parameters in patients with secondary hemophagocytic lymphohistiocytosis.
- Hemophagocytic lymphohistiocytosis with a hemizygous PRF1 c.674G>A mutation.
- Clinical and genetic characterization of Epstein-Barr virus-associated T/NK-cell lymphoproliferative diseases.
- Clinical profile, etiology, and outcome of hemophagocytic lymphohistiocytosis associated with histiocytic necrotizing lymphadenitis.
- The superiority of Epstein-Barr virus DNA in plasma over in peripheral blood mononuclear cells for monitoring EBV-positive NK-cell lymphoproliferative diseases.
- Tuberculosis infection related hemophagocytic lymphohistiocytosis diagnosed in patient with GZMB mutation: A case report and literature review.
- Excessive IL-10 and IL-18 trigger hemophagocytic lymphohistiocytosis-like hyperinflammation and enhanced myelopoiesis.
- Clinical analysis and a novel risk predictive nomogram for 155 adult patients with hemophagocytic lymphohistiocytosis.
- Clinical and genetic features of Epstein-Barr virus-triggered late-onset primary hemophagocytic lymphohistiocytosis: Ten pedigrees study.
- Clinical Characteristics of Hemophagocytic Lymphohistiocytosis Associated with Non-Hodgkin B-Cell Lymphoma: A Multicenter Retrospective Study.
- Infection-associated Hemophagocytic Syndrome in Critically Ill Patients with COVID-19.
- Germline variants in UNC13D and AP3B1 are enriched in COVID-19 patients experiencing severe cytokine storms.
All its trials on ClinicalTrials.gov, any status1
More papers found outside PubMed (not counted)6
- Dendritic cell–based vaccines (KSD-101) against EBV-associated lymphoproliferative diseases: Results from an ongoing phase I clinical study.
- Humanized anti-CD25 monoclonal antibody for previously treated hemophagocytic lymphohistiocytosis in adults: A prospective, open-label clinical trial
- CLAMP: A phase II prospective study of camrelizumab combined with pegaspargase, etoposide, and high-dose methotrexate in patients with natural killer (NK)/T-cell lymphoma.
- Clinical analysis of seven cases of hemophagocytic lymphohistiocytosis secondary to cutaneous T-cell lymphoma
- Ksd-101 in Patients with EBV-Associated Hematologic Neoplasms: Results from an Ongoing Phase I Clinical Study
- Outcomes of PD-1 Inhibitors Treatment of Chronic Active Epstein Barr Virus Infection : A Single Center Retrospective Analysis
Blood disorders
Beta thalassaemia
β 地中海贫血Led no English-language PubMed papers on beta thalassaemia in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
4 hospitals in Wuhan for beta thalassaemia157 hospitals in China for beta thalassaemia
No open trial on beta thalassaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Earlier papers (2016–2020)1
Blood disorders
Haemophilia A
血友病 ALed 4 of the 272 English-language PubMed papers on haemophilia A with an author in mainland China, 2021–2025: 1.5%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
2 hospitals in Wuhan for haemophilia A160 hospitals in China for haemophilia A
Open trials with this hospital 2
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
- Phase
- Phase 3
- Started
- 2022-12
- Registry
- NCT05611801
Age 1 year to 17 years; men only (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Tianjin, Wuhan
- RecruitingOpen-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
- Phase
- Phase 3
- Started
- 2021-11
- Registry
- NCT05145127
Age 1 year to 74 years; men only (registered criteria)
Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesBeijing, Guangzhou, Guiyang, Nanchang, Tianjin, Wuhan
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led4
- Investigation and Analysis of the Current Status of Health-Related Quality of Life in Adolescents with Hemophilia in Hubei Province.
- Clinical Analysis and Mental Health Survey of Hemophilia Carriers: a Cross-sectional Study.
- An aberrant F8 intron 1 inversion with concomitant large duplication and deletion in a Chinese severe hemophilia A patient.
- TWIN BROTHERS WITH VARIABLE PHENOTYPES OF HAEMOPHILIA A RESULTING FROM MATERNAL MOSAICISM OF ARG550CYS OF F8.
Chinese-language papers (not in the count)1
Earlier papers (2016–2020)8
- Management of haemophilia patients in the COVID-19 pandemic: Experience in Wuhan and Tianjin, two differently affected cities in China.
- Clinical findings in a patient with haemophilia A affected by COVID-19.
- Determining the cutoff value of the APTT mixing test for factor VIII inhibitor.
- F8 IVS9+5G>A mutation causes moderate haemophilia A.
- A Retrospective Analysis of Intracranial Hemorrhage in Children with Hemophilia A.
- Performance of next-generation sequencing in the detection of large exon deletion in patients of haemophilia A.
- Two-incision laparoscopic appendectomy for a severe hemophilia A child patient with coagulation factor VII deficiency: Case report and review of literature.
- [Study of gene mutation in 62 hemophilia A children].
All its trials on ClinicalTrials.gov, any status11
- A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
- Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
- Study of Efficacy and Safety of FRSW107 in Pediatric Patients With Severe Hemophilia A
- A Study of Adynovate in Previously Treated Chinese Teenagers and Adults With Severe Hemophilia A
- A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A
- A Research Study Investigating Mim8 in Adults and Adolescents With Haemophilia A With or Without Inhibitors
- A Study to Evaluate the Safety and Pharmacokinetic of Recombinant Human Coagulation Factor VIII ,Fc Fusion Protein for Injection
- PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Hemophilia A
- Retrospective Chart Review to Evaluate Safety and Tolerability of ADVATE Among Previously Untreated Patients in China With Moderate to Severe Hemophilia A
- China ADVATE PTP Study
- ADVATE/ ADYNOVI Hemophilia A Outcome Database (AHEAD)
Blood disorders
Thrombotic thrombocytopenic purpura
血栓性血小板减少性紫癜Led 6 of the 64 English-language PubMed papers on thrombotic thrombocytopenic purpura with an author in mainland China, 2021–2025: 9.4%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
1 hospital in Wuhan for thrombotic thrombocytopenic purpura59 hospitals in China for thrombotic thrombocytopenic purpura
No open trial on thrombotic thrombocytopenic purpura lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led6
- Improving the PLASMIC score with the use of RDW-SD in the differential diagnosis for thrombotic thrombocytopenic purpura in Chinese patients.
- Prognostic value of laboratory biomarkers for mortality risk stratification in thrombotic thrombocytopenic purpura.
- A Novel Variant on the Thrombospondin Type-1 Repeat 2 Domain of ADAMTS13 in a Parturient with Suspected Hereditary Thrombotic Thrombocytopenic Purpura and Unusually High ADAMTS13 Activity.
- Identification of 8 Rare Deleterious Variants in ADAMTS13 by Next-generation Sequencing in a Chinese Population with Thrombotic Thrombocytopenic Purpura.
- A Case of Parturient with Hereditary Thrombotic Thrombocytopenic Purpura: Case Report of a Novel Variant.
- Thrombotic thrombocytopenic purpura complicated with acute aortic dissection: A case report.
Chinese-language papers (not in the count)1
Earlier papers (2016–2020)2
All its trials on ClinicalTrials.gov, any status1
Other diseases
Neuromyelitis optica spectrum disorder
视神经脊髓炎谱系疾病Led 18 of the 485 English-language PubMed papers on neuromyelitis optica spectrum disorder with an author in mainland China, 2021–2025: 3.7%.
2 hospitals in Wuhan for neuromyelitis optica spectrum disorder67 hospitals in China for neuromyelitis optica spectrum disorder
Open trials with this hospital 8
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingSafety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.
- Phase
- Phase 1
- Started
- 2026-04
- Registry
- NCT07526493
Age 18 years to 75 years (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingThe Safety and Efficacy of NouvSoma001 in Neuromyelitis Optica Spectrum Disorders
- Phase
- Phase 1
- Started
- 2025-03
- Registry
- NCT06620809
Age 18 years to 65 years (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingMonoclonal Antibody-Based Therapies for AQP4-Positive NMOSD
- Phase
- Not given
- Started
- 2025-07
- Registry
- NCT06885957
Age 18 years to 65 years (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingEfficacy and Safety of Calculus Bovis Sativus (CBS) for Idiopathic Inflammatory Demyelinating Disease (CBSinIIDD)
- Phase
- N/A
- Started
- 2024-08
- Registry
- NCT06474520
Age 18 years to Not stated (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingBiomarkers in Autoimmune Disease of Nervous System
- Phase
- Not given
- Started
- 2024-07
- Registry
- NCT06502015
Age 18 years to Not stated (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingSafety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System
- Phase
- Early phase 1
- Started
- 2020-09
- Registry
- NCT04561557
Age 18 years to 75 years (registered criteria)
Led by Tongji HospitalWuhan
- Not yet recruitingTongji NADs Cohort
- Phase
- Not given
- Started
- 2026-03
- Registry
- NCT07333196
Age 18 years to 80 years (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingA Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
- Phase
- Phase 2/Phase 3
- Started
- 2024-07
- Registry
- NCT06413654
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xiamen, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led18
- Quantitative Contribution of Clinical Attacks to Residual Disability in Patients With AQP4-Antibody Neuromyelitis Optica Spectrum Disorder.
- Soluble TREM2 triggers microglial dysfunction in neuromyelitis optica spectrum disorders.
- Segmental abnormalities of white matter microstructure in multiple sclerosis and neuromyelitis optica spectrum disorder identified by automated fiber quantification.
- Serum LDL Promotes Microglial Activation and Exacerbates Demyelinating Injury in Neuromyelitis Optica Spectrum Disorder.
- Single-cell analysis of anti-BCMA CAR T cell therapy in patients with central nervous system autoimmunity.
- Astrocyte-Derived Exosomes Contribute to Pathologies of Neuromyelitis Optica Spectrum Disorder in Rodent Model.
- Research hotspots and trends on neuromyelitis optica spectrum disorders: insights from bibliometric analysis.
- Editorial: Immune Mechanisms in white matter lesions: Clinical and pathophysiological implications.
- TREM2 deficiency inhibits microglial activation and aggravates demyelinating injury in neuromyelitis optica spectrum disorder.
- Structural covariance in subcortical regions in multiple sclerosis and neuromyelitis optica spectrum disorders: An MRI-based study with automated brain volumetry.
- Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim results.
- Fractional anisotropy helps to differentiate the optic nerve impairment between neuromyelitis optica spectrum disorders and multiple sclerosis.
- Comparison of clinical and radiological characteristics in autoimmune GFAP astrocytopathy, MOGAD and AQP4-IgG+ NMOSD mimicking intracranial infection as the initial manifestation.
- Distinct Immunological Features of Inflammatory Demyelinating Diseases of the Central Nervous System.
- Case Report: Clinical and Imaging Characteristics of a Patient with Anti-flotillin Autoantibodies: Neuromyelitis Optica or Multiple Sclerosis?
- Dynamic Changes in AQP4-IgG Level and Immunological Markers During Protein-A Immunoadsorption Therapy for NMOSD: A Case Report and Literature Review.
- Regulatory T cells protect against brain damage by alleviating inflammatory response in neuromyelitis optica spectrum disorder.
- Modified models to distinguish central nervous system demyelinating diseases with brain lesions.
All its trials on ClinicalTrials.gov, any status9
- Tongji NADs Cohort
- Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.
- Monoclonal Antibody-Based Therapies for AQP4-Positive NMOSD
- The Safety and Efficacy of NouvSoma001 in Neuromyelitis Optica Spectrum Disorders
- Biomarkers in Autoimmune Disease of Nervous System
- Efficacy and Safety of Calculus Bovis Sativus (CBS) for Idiopathic Inflammatory Demyelinating Disease (CBSinIIDD)
- Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System
- A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
- A Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders
More papers found outside PubMed (not counted)3
- A Real-World Study of Inebilizumab in Patients with Neuromyelitis Optica Spectrum Disorder (P11-8.012)
- Anti-BCMA CAR T-CELL therapy CT103A in relapsed or refractory AQP4-IGG seropositive neuromyelitis optica spectrum disorders: Phase 1 trial interim results
- Contribution of clinical attacks to the irreversible disability in NMOSD (S50.007)
Other diseases
IgG4-related disease
IgG4相关性疾病Led 11 of the 246 English-language PubMed papers on IgG4-related disease with an author in mainland China, 2021–2025: 4.5%.
2 hospitals in Wuhan for IgG4-related disease46 hospitals in China for IgG4-related disease
Open trials with this hospital 3
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingSafety and Efficacy of PRG-2311 for Refractory Lupus Nephritis and IgG4-Related Disease
- Phase
- Early phase 1
- Started
- 2024-07
- Registry
- NCT06497361
Age 18 years to Not stated (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingSafety and Efficacy of PRG-1801 for Refractory Lupus Nephritis and IgG4-Related Disease
- Phase
- Early phase 1
- Started
- 2024-07
- Registry
- NCT06497387
Age 18 years to Not stated (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingStudy to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease
- Phase
- Phase 1/Phase 2
- Started
- 2026-01
- Registry
- NCT07061938
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Chengdu, Shanghai, Wuhan
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led11
- Thalidomide can effectively prevent relapse in IgG4-related disease outweighing its side effects: a multicentre, randomised, double-blinded, placebo-controlled study.
- Omics in IgG4-related disease.
- Serum N-Glycan Signatures as Potential Biomarkers for the Detection and Monitoring of IgG4-Related Disease.
- BLyS/APRIL dual inhibition for IgG4-RD: a prospective single-arm clinical trial of telitacicept.
- Clinical value of 18F-FDG PET/CT in IgG4-related disease.
- Update on classification, diagnosis, and management of immunoglobulin G4-related disease.
- Role of eosinophilia in IgG4-related disease.
- Multi-System Langerhans Cell Histiocytosis as a Mimic of IgG4-Related Disease: A Case Report and Literature Review.
- Proteomic characteristics of saliva in patients with different subgroups of IgG4-RD.
- Potential roles of non-lymphocytic cells in the pathogenesis of IgG4-related disease.
- IgG4-Related Disease: A Retrospective Chinese Study of Features and Treatment Response of 98 Patients Including 4 Rare Cases.
All its trials on ClinicalTrials.gov, any status5
- Safety and Efficacy of PRG-1801 for Refractory Lupus Nephritis and IgG4-Related Disease
- Safety and Efficacy of PRG-2311 for Refractory Lupus Nephritis and IgG4-Related Disease
- the Safety and Efficacy of Targeted BCMA In Vivo LV Injection for Recurrent or Refractory Autoimmune Diseases
- Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease
- A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease
More papers found outside PubMed (not counted)4
- Potential roles of antibodies with different classes in IgG4‐related diseases
- Case Report: A Rare Manifestation of IgG4 ‐Related Disease: Isolated Hepatocellular Injury
- POS0347 INSIGHTS INTO THE DESIGN AND STUDY POPULATION OF MITIGATE: THE FIRST MULTINATIONAL RANDOMIZED CONTROLLED CLINICAL TRIAL IN IgG4 RELATED DISEASE (IgG4-RD), EVALUATING THE EFFICACY AND SAFETY OF INEBILIZUMAB
- IgG4-Related Disease
Other diseases
Myasthenia gravis
重症肌无力Led 17 of the 499 English-language PubMed papers on myasthenia gravis with an author in mainland China, 2021–2025: 3.4%.
3 hospitals in Wuhan for myasthenia gravis93 hospitals in China for myasthenia gravis
Open trials with this hospital 9
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingSafety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.
- Phase
- Phase 1
- Started
- 2026-04
- Registry
- NCT07526493
Age 18 years to 75 years (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingGC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis(24103)
- Phase
- Early phase 1
- Started
- 2025-07
- Registry
- NCT07058298
Age 18 years to 75 years (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingCD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases
- Phase
- Early phase 1
- Started
- 2025-12
- Registry
- NCT07337785
Age 18 years to 70 years (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingBiomarkers in Autoimmune Disease of Nervous System
- Phase
- Not given
- Started
- 2024-07
- Registry
- NCT06502015
Age 18 years to Not stated (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingSafety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System
- Phase
- Early phase 1
- Started
- 2020-09
- Registry
- NCT04561557
Age 18 years to 75 years (registered criteria)
Led by Tongji HospitalWuhan
- Not yet recruitingTongji NADs Cohort
- Phase
- Not given
- Started
- 2026-03
- Registry
- NCT07333196
Age 18 years to 80 years (registered criteria)
Led by Tongji HospitalWuhan
- Not yet recruitingUniversal STAR-T Cell Injection in Generalized Myasthenia Gravis
- Phase
- Phase 1
- Started
- 2026-07
- Registry
- NCT07714798
Age 18 years to 65 years (registered criteria)
Led by Tongji HospitalWuhan
- Not yet recruitingA Clinical Study to Evaluate the Safety and Efficacy of GT802 Injection in the Treatment of Refractory Generalized Myasthenia Gravis
- Phase
- Early phase 1
- Started
- 2026-12
- Registry
- NCT07917923
Age 18 years to 65 years (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingEfficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
- Phase
- Phase 3
- Started
- 2024-06
- Registry
- NCT06463587
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Guangzhou, Shanghai, Shenyang, Shijiazhuang, Wuhan, Zhengzhou, Zunyi
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led17
- Perioperative Efgartigimod treatment for acute myasthenia gravis exacerbation with retroperitoneal mass: a case report.
- The real-world impact of corticosteroid-associated adverse events in myasthenia gravis: A patient-reported survey analysis.
- The JAK1/3 Inhibitor Tofacitinib Regulates Th Cell Profiles and Humoral Immune Responses in Myasthenia Gravis.
- Long-term efficacy and safety of tacrolimus in anti-MuSK antibody-positive myasthenia gravis: a retrospective single-center cohort study.
- Type B thymomas in patients with myasthenia gravis display a distinctive pattern of αβ TCR and IL-7 receptor α expression on CD4+CD8+ thymocytes.
- B cell lineage reconstitution underlies CAR-T cell therapeutic efficacy in patients with refractory myasthenia gravis.
- Exhausted signature and regulatory network of NK cells in myasthenia gravis.
- Effect of thymectomy on the frequencies of peripheral regulatory B and T lymphocytes in patients with Myasthenia gravis-a pilot study.
- Development and validation of the scale for symptom clusters in patients with myasthenia gravis.
- Clinical and immune-related factors associated with exacerbation in adults with well-controlled generalized myasthenia gravis.
- Effects of symptom clusters on quality of life mediated by self-efficacy among individuals with myasthenia gravis: A structural equation modelling analysis.
- Dynamic nomogram for predicting generalized conversion in adult-onset ocular myasthenia gravis.
- Clinical Features, Treatment, and Prognostic Factors of Childhood-Onset Myasthenia Gravis in a Large Chinese Cohort.
- Childhood-Onset Myasthenia Gravis Patients Benefited from Thymectomy in a Long-Term Follow-up Observation.
- Subxiphoid-subcostal thoracoscopic thymectomy for seropositive myasthenia offers equivalent remission rates and potentially faster recovery.
- Differences in immunophenotypes between myasthenia gravis patients with and without thyroid antibodies.
- Upregulation of circ-FBL promotes myogenic proliferation in myasthenia gravis by regulation of miR-133/PAX7.
All its trials on ClinicalTrials.gov, any status13
- Tongji NADs Cohort
- Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.
- CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases
- Biomarkers in Autoimmune Disease of Nervous System
- Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System
- Universal STAR-T Cell Injection in Generalized Myasthenia Gravis
- A Clinical Study to Evaluate the Safety and Efficacy of GT802 Injection in the Treatment of Refractory Generalized Myasthenia Gravis
- GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis(24103)
- Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
- A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis
- A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis
- Study of Telitacicept in Generalized Myasthenia Gravis
- A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis
Other diseases
Moyamoya disease
烟雾病Led 3 of the 356 English-language PubMed papers on moyamoya disease with an author in mainland China, 2021–2025: 0.8%.
- Open trials as a site
- 0
- led by another institution
3 hospitals in Wuhan for moyamoya disease47 hospitals in China for moyamoya disease
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingTreatment of Moyamoya Disease With iPSC-derived Exosomes
- Phase
- Phase 1
- Started
- 2025-05
- Registry
- NCT07065409
Age 18 years to 75 years (registered criteria)
Led by Tongji HospitalWuhan
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led3
- Comparative study on acute management of intracerebral haematoma using local thrombolysis in moyamoya and non-moyamoya patients: a single institution experience.
- Endothelial Cell-Derived Let-7c-Induced TLR7 Activation on Smooth Muscle Cell Mediate Vascular Wall Remodeling in Moyamoya Disease.
- CircZXDC Promotes Vascular Smooth Muscle Cell Transdifferentiation via Regulating miRNA-125a-3p/ABCC6 in Moyamoya Disease.
All its trials on ClinicalTrials.gov, any status1
More papers found outside PubMed (not counted)1
Other diseases
Biliary atresia
胆道闭锁Led 2 of the 214 English-language PubMed papers on biliary atresia with an author in mainland China, 2021–2025: 0.9%.
- Open trials as a site
- 0
- led by another institution
2 hospitals in Wuhan for biliary atresia28 hospitals in China for biliary atresia
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingNutritional Intervention for Biliary Atresia
- Phase
- N/A
- Started
- 2025-02
- Registry
- NCT06764082
Age 1 day to 3 months (registered criteria)
Led by Tongji HospitalWuhan
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led2
All its trials on ClinicalTrials.gov, any status2
More papers found outside PubMed (not counted)2
Other diseases
Anti-NMDA receptor encephalitis
抗 NMDA 受体脑炎Led 2 of the 264 English-language PubMed papers on anti-NMDA receptor encephalitis with an author in mainland China, 2021–2025: 0.8%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
5 hospitals in Wuhan for anti-NMDA receptor encephalitis126 hospitals in China for anti-NMDA receptor encephalitis
No open trial on anti-NMDA receptor encephalitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led2
Earlier papers (2016–2020)1
Other diseases
Idiopathic pulmonary fibrosis
特发性肺纤维化Led 14 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 1.4%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
9 hospitals in Wuhan for idiopathic pulmonary fibrosis333 hospitals in China for idiopathic pulmonary fibrosis
No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led14
- Associations between dietary patterns and the incidence of idiopathic pulmonary fibrosis: A cohort study.
- Semaphorin 3E-Plexin D1 Axis Drives Lung Fibrosis through ErbB2-Mediated Fibroblast Activation.
- Targeting PBK in the fibroblast-to-myofibroblast transition: A novel therapeutic strategy for IPF.
- Six1 promotes alveolar epithelium senescence in pulmonary fibrosis through regulating Tp53.
- Alpinetin ameliorates bleomycin-induced pulmonary fibrosis by repressing fibroblast differentiation and proliferation.
- Localized Administration of Bcar3 siRNA via Nano-Self-Assembly to Treat Idiopathic Pulmonary Fibrosis by Disrupting Macrophage-Fibroblast Crosstalk.
- Imaging Pulmonary Fibrosis and Treatment Efficacy In Vivo with Autotaxin-Specific PET Ligand [18F]ATX-1905.
- Regulation of myofibroblast dedifferentiation in pulmonary fibrosis.
- Lung Transplantation: A Viable Option for Connective Tissue Disease?
- Genetic Programs Between Steroid-Sensitive and Steroid-Insensitive Interstitial Lung Disease.
- The Role of Immune Cells in the Pathogenesis of Idiopathic Pulmonary Fibrosis.
- The methyl-CpG-binding domain 2 facilitates pulmonary fibrosis by orchestrating fibroblast to myofibroblast differentiation.
- A nonsynonymous polymorphism (rs117179004, T392M) of hyaluronidase 1 (HYAL1) is associated with increased risk of idiopathic pulmonary fibrosis in Southern Han Chinese.
- Suppressing Sart1 to modulate macrophage polarization by siRNA-loaded liposomes: a promising therapeutic strategy for pulmonary fibrosis.
Earlier papers (2016–2020)10
- Indirubin alleviates bleomycin-induced pulmonary fibrosis in mice by suppressing fibroblast to myofibroblast differentiation.
- Response.
- Response.
- Viral Infection Increases the Risk of Idiopathic Pulmonary Fibrosis: A Meta-Analysis.
- Blocking protein phosphatase 2A with a peptide protects mice against bleomycin-induced pulmonary fibrosis.
- Pirfenidone facilitates immune infiltration and enhances the antitumor efficacy of PD-L1 blockade in mice.
- Curdione ameliorates bleomycin-induced pulmonary fibrosis by repressing TGF-β-induced fibroblast to myofibroblast differentiation.
- Autophagy inhibition-mediated epithelial-mesenchymal transition augments local myofibroblast differentiation in pulmonary fibrosis.
- Targeted resequencing reveals genetic risks in patients with sporadic idiopathic pulmonary fibrosis.
- Macrophages: friend or foe in idiopathic pulmonary fibrosis?
All its trials on ClinicalTrials.gov, any status8
- A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
- A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
- A Multiple Ascending Doses (MAD) Study of PMG1015 in Idiopathic Pulmonary Fibrosis Subjects
- A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
- A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis
- A Study to Evaluate Long Term Safety and Efficacy of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis
- Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
- Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
Other diseases
Lymphangioleiomyomatosis
肺淋巴管平滑肌瘤病Led 1 of the 45 English-language PubMed papers on lymphangioleiomyomatosis with an author in mainland China, 2021–2025: 2.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Wuhan for lymphangioleiomyomatosis28 hospitals in China for lymphangioleiomyomatosis
No open trial on lymphangioleiomyomatosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led1
Earlier papers (2016–2020)1
Other diseases
Amyotrophic lateral sclerosis
肌萎缩侧索硬化症Led 11 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 1.4%.
- Open trials as a site
- 0
- led by another institution
6 hospitals in Wuhan for amyotrophic lateral sclerosis194 hospitals in China for amyotrophic lateral sclerosis
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Study to Evaluate the Tolerability, Safety and Efficacy of VGN-R13 in Patients with ALS
- Phase
- Early phase 1
- Started
- 2025-01
- Registry
- NCT06849609
Age 18 years to Not stated (registered criteria)
Led by Tongji HospitalWuhan
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led11
- Cd16-Cd56bright NK Cells: A Protective NK Cell Subset for Progression and Prognosis in Amyotrophic Lateral Sclerosis.
- White matter integrity mediated the effect of plasma uric acid levels on cognitive function in ALS patients.
- Association between cardiac autonomic dysfunction, cognitive impairment, and survival in patients with amyotrophic lateral sclerosis.
- Astrocytes Contribute to Motor Neuron Degeneration in ALS via the TRAIL-DR5 Signaling Pathway.
- Association between apathy and caregiver burden in patients with amyotrophic lateral sclerosis: a cross-sectional study.
- Quantitative MRI Analysis of Brachial Plexus and Limb-Girdle Muscles in Upper Extremity Onset Amyotrophic Lateral Sclerosis.
- Brain-derived neurotrophic factor/tropomyosin receptor kinase B signaling in spinal muscular atrophy and amyotrophic lateral sclerosis.
- The level of homocysteine in amyotrophic lateral sclerosis: a systematic review and meta-analysis.
- Cardiovascular comorbidities in amyotrophic lateral sclerosis: A systematic review.
- Decreased blood CD4+ T lymphocyte helps predict cognitive impairment in patients with amyotrophic lateral sclerosis.
- The illness experience for people with amyotrophic lateral sclerosis: A qualitative study.
Earlier papers (2016–2020)3
All its trials on ClinicalTrials.gov, any status1
Other diseases
Fabry disease
法布雷病Led no English-language PubMed papers on Fabry disease in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Wuhan for Fabry disease85 hospitals in China for Fabry disease
No open trial on Fabry disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Duchenne muscular dystrophy
杜氏肌营养不良Led 2 of the 213 English-language PubMed papers on Duchenne muscular dystrophy with an author in mainland China, 2021–2025: 0.9%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Wuhan for Duchenne muscular dystrophy116 hospitals in China for Duchenne muscular dystrophy
No open trial on Duchenne muscular dystrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Behçet disease
白塞病Led 1 of the 245 English-language PubMed papers on Behçet disease with an author in mainland China, 2021–2025: 0.4%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
7 hospitals in Wuhan for Behçet disease149 hospitals in China for Behçet disease
No open trial on Behçet disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led1
Earlier papers (2016–2020)1
Other diseases
Alport syndrome
Alport 综合征Led 2 of the 58 English-language PubMed papers on Alport syndrome with an author in mainland China, 2021–2025: 3.5%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Wuhan for Alport syndrome60 hospitals in China for Alport syndrome
No open trial on Alport syndrome lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led2
All its trials on ClinicalTrials.gov, any status1
Other diseases
IgA nephropathy
IgA 肾病Led 21 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 2.9%.
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
8 hospitals in Wuhan for IgA nephropathy346 hospitals in China for IgA nephropathy
No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led21
- Prognosis and predictive factors in pediatric IgA nephropathy.
- Identifying the potential therapeutic targets of tertiary lymphoid structure in IgA nephropathy based on bioinformatics.
- Pathogenic synonymous variation of the COL4A3 gene causing Alport syndrome comorbid with IgA deposition in a toddler: a case report.
- Network Pharmacological Analysis of Hydroxychloroquine Intervention in the Treatment of Iga Nephropathy.
- Efficacy and Safety of Telitacicept in IgA Nephropathy and IgA Vasculitis-Associated Nephritis in Children: A Retrospective Single-Centre Study.
- Efficacy and Long-Term Outcomes of Tacrolimus versus Cyclophosphamide and Mycophenolate Mofetil in the Management of Pediatric IgA Vasculitis Nephritis: A Cohort Study in Single-Center.
- Development and Validation of a Predictive Model for Severe Tubular Atrophy/Interstitial Fibrosis in Patients with IgA Nephropathy: Multicenter Retrospective Study.
- Exploring the Relationship Between 91 Inflammatory Cytokines and IgA Nephropathy Using a Two-Sample Mendelian Randomization Study and the Gene Expression Omnibus Database.
- Efficacy and safety of telitacicept in children with IgA vasculitis and IgA vasculitis nephritis: a single-center retrospective study.
- Circulating soluble CD30 is associated with renal tertiary lymphoid structures and the progression of IgA nephropathy.
- Exploring the causal effect of complement and IgA nephropathy-a Mendelian randomization study.
- High Renal Mast Cell Density Is Associated with Poor Prognosis in Patients with Immunoglobulin A Nephropathy.
- T Follicular Helper Cells in Tertiary Lymphoid Structure Contribute to Renal Fibrosis by IL-21.
- Noninvasive Assessment of the Renal Function, Oxford Classification and Prognostic Risk Stratification of IgAN by Using Intravoxel Incoherent Motion Diffusion-Weighted Imaging and Blood Oxygenation Level-Dependent MRI.
- Shrunken Pore Syndrome Is Associated with Renal Function Decline in Female Patients with Kidney Diseases.
- Clinical and Pathological Implications of Increases in Tonsillar CD19+CD5+ B Cells, CD208+ Dendritic Cells, and IgA1-positive Cells of Immunoglobulin A Nephropathy.
- CD137L-macrophage induce lymphatic endothelial cells autophagy to promote lymphangiogenesis in renal fibrosis.
- Interleukin-7 Is Associated with Clinical and Pathological Activities in Immunoglobulin A Nephropathy and Protects the Renal Proximal Tubule Epithelium from Cellular Fibrosis.
- Severe glomerular C3 deposition indicates severe renal lesions and a poor prognosis in patients with immunoglobulin A nephropathy.
- The prognostic value of platelet-to-lymphocyte ratio on the long-term renal survival in patients with IgA nephropathy.
- Tertiary lymphoid organs are associated with the progression of kidney damage and regulated by interleukin-17A.
Chinese-language papers (not in the count)1
Earlier papers (2016–2020)6
- Clinical and pathological findings of SARS-CoV-2 infection and concurrent IgA nephropathy: a case report.
- High renal DC-SIGN+ cell density is associated with severe renal lesions and poor prognosis in patients with immunoglobulin A nephropathy.
- Plasma fractalkine levels are associated with renal inflammation and outcomes in immunoglobulin A nephropathy.
- Tacrolimus decreases proteinuria in patients with refractory IgA nephropathy.
- [Clinical efficacy of tonsillectomy in renal transplant patients with recurrent IgA nephropathy].
- Decreased DACH1 expression in glomerulopathy is associated with disease progression and severity.
All its trials on ClinicalTrials.gov, any status2
Other diseases
Gaucher disease
戈谢病Led no English-language PubMed papers on Gaucher disease in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
1 hospital in Wuhan for Gaucher disease41 hospitals in China for Gaucher disease
No open trial on Gaucher disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
Other diseases
Niemann–Pick disease type C
尼曼-匹克病 C 型Led no English-language PubMed papers on Niemann–Pick disease type C in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
1 hospital in Wuhan for Niemann–Pick disease type C15 hospitals in China for Niemann–Pick disease type C
No open trial on Niemann–Pick disease type C lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Osteogenesis imperfecta
成骨不全症Led no English-language PubMed papers on osteogenesis imperfecta in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Wuhan for osteogenesis imperfecta59 hospitals in China for osteogenesis imperfecta
No open trial on osteogenesis imperfecta lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
Other diseases
Primary biliary cholangitis
原发性胆汁性胆管炎Led 2 of the 300 English-language PubMed papers on primary biliary cholangitis with an author in mainland China, 2021–2025: 0.7%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
5 hospitals in Wuhan for primary biliary cholangitis173 hospitals in China for primary biliary cholangitis
No open trial on primary biliary cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led2
All its trials on ClinicalTrials.gov, any status1
Other diseases
Hirschsprung disease
先天性巨结肠Led 13 of the 161 English-language PubMed papers on Hirschsprung disease with an author in mainland China, 2021–2025: 8.1%.
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Wuhan for Hirschsprung disease82 hospitals in China for Hirschsprung disease
No open trial on Hirschsprung disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led13
- Analysis of the causes of redo pull-through for recurrent constipation and the risk factors affecting the prognosis of the Hirschsprung's disease: a single-center retrospective study and systematic review.
- EMB is essential for enteric nervous system development mediated by PI3K signaling.
- Rare and common genetic variants underlying the risk of Hirschsprung's disease.
- Identification of signaling pathways that specify a subset of migrating enteric neural crest cells at the wavefront in mouse embryos.
- Mesenchymal Stem Cells Attenuates Hirschsprung diseases - Associated Enterocolitis by Reducing M1 Macrophages Infiltration via COX-2 Dependent Mechanism.
- Screening of undernutrition in children with Hirschsprung disease using preoperative anthropometric parameters: A multicenter cross-sectional study.
- Abnormally elevated expression of ACTA2 of circular smooth muscle leads to hyperactive contraction in aganglionic segments of HSCR.
- Comprehensive characterization of the genetic landscape of familial Hirschsprung's disease.
- Identification and validation of the common pathogenesis and hub biomarkers in Hirschsprung disease complicated with Crohn's disease.
- Down-Regulation of Double C2 Domain Alpha Promotes the Formation of Hyperplastic Nerve Fibers in Aganglionic Segments of Hirschsprung's Disease.
- Transanal full-thickness pull-through approach in the treatment of anastomotic leakage after operation for Hirschsprung disease.
- NOX5 is expressed aberrantly but not a critical pathogenetic gene in Hirschsprung disease.
- Benzophenone-3 induced abnormal development of enteric nervous system in zebrafish through MAPK/ERK signaling pathway.
Earlier papers (2016–2020)12
- Long-term outcomes of single-incision laparoscopic technique in Soave procedure compared with heart-shaped anastomosis for Hirschsprung disease.
- Long-term outcomes of laparoscope-assisted heart-shaped anastomosis for children with hirschsprung disease: A 10-year review study.
- Thyroid Hormone in the Pathogenesis of Congenital Intestinal Dysganglionosis.
- Optimal time for single-stage pull-through colectomy in infants with short-segment Hirschsprung disease.
- Results of rectoanal manometry after a novel laparoscopic technique: laparoscope-assisted heart-shaped anastomosis for Hirschsprung's disease.
- A Long-Term Follow-Up of a New Surgery Method: Laparoscope-Assisted Heart-Shaped Anastomosis for Hirschsprung's Disease.
- Diagnostic value of the preoperatively detected radiological transition zone in Hirschsprung's disease.
- A de novo deletion mutation in SOX10 in a Chinese family with Waardenburg syndrome type 4.
- Novel Insights into the Pathogenesis of Hirschsprung's-associated Enterocolitis.
- Laparoscopy-assisted versus transabdominal reoperation in Hirschprung's disease for residual aganglionosis and transition zone pathology after transanal pull-through.
- Single-incision laparoscopic versus conventional laparoscopic surgery for Hirschsprung's disease: A comparison of medium-term outcomes.
- Pathological changes of interstitial cells of Cajal and ganglion cells in the segment of resected bowel in Hirschsprung's disease.
All its trials on ClinicalTrials.gov, any status5
- Nutrition Support for Hirschsprung Disease
- A Trial on Treatments of Hirschsprung Allied Disease
- Comparison of Circular(Soave) and Heart-shaped Anastomosis in Hirschsprung's Disease
- Fast-track Surgery in the Treatment of Hirschsprung's Disease
- A New Scoring System Improves Diagnostic Accuracy of Intestinal Dysganglionosis --a Prospective Study
Other diseases
Inherited epidermolysis bullosa
遗传性大疱性表皮松解症Led no English-language PubMed papers on inherited epidermolysis bullosa in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
1 hospital in Wuhan for inherited epidermolysis bullosa41 hospitals in China for inherited epidermolysis bullosa
No open trial on inherited epidermolysis bullosa lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Hereditary angioedema
遗传性血管性水肿Led 1 of the 32 English-language PubMed papers on hereditary angioedema with an author in mainland China, 2021–2025: 3.1%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
1 hospital in Wuhan for hereditary angioedema30 hospitals in China for hereditary angioedema
No open trial on hereditary angioedema lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led1
Other diseases
Familial adenomatous polyposis
家族性腺瘤性息肉病Led no English-language PubMed papers on familial adenomatous polyposis in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
4 hospitals in Wuhan for familial adenomatous polyposis76 hospitals in China for familial adenomatous polyposis
No open trial on familial adenomatous polyposis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Leber hereditary optic neuropathy
Leber 遗传性视神经病变Led 2 of the 52 English-language PubMed papers on Leber hereditary optic neuropathy with an author in mainland China, 2021–2025: 3.9%.
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Wuhan for Leber hereditary optic neuropathy32 hospitals in China for Leber hereditary optic neuropathy
No open trial on Leber hereditary optic neuropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led2
Earlier papers (2016–2020)10
- Factors associated with rapid improvement in visual acuity in patients with Leber's hereditary optic neuropathy after gene therapy.
- Multilocus Mitochondrial Mutations Do Not Directly Affect the Efficacy of Gene Therapy for Leber Hereditary Optic Neuropathy.
- Seven-Year Follow-up of Gene Therapy for Leber's Hereditary Optic Neuropathy.
- What are the characteristics and progression of visual field defects in patients with Leber hereditary optic neuropathy: a prospective single-centre study in China.
- Clinical Observation of Patients with Leber's Hereditary Optic Neuropathy Before Gene Therapy.
- Visual Acuity Testing Before and After Intravitreal Injection of rAAV2-ND4 in Patients.
- Visual Field Variability after Gene Therapy for Leber's Hereditary Optic Neuropathy.
- Long-term outcomes of gene therapy for the treatment of Leber's hereditary optic neuropathy.
- Evaluation of Leber's hereditary optic neuropathy patients prior to a gene therapy clinical trial.
- Efficacy and Safety of rAAV2-ND4 Treatment for Leber's Hereditary Optic Neuropathy.
All its trials on ClinicalTrials.gov, any status2
Getting in touch
Name card to show staff or a driver
华中科技大学同济医学院附属同济医院
Tongji Hospital
武汉
Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.
Inquiry letter in English and Chinese
Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.
Records hospitals usually ask for
- A recent summary or letter from the treating doctor
- Pathology report
- Scans (CT, MRI, PET) with their reports, and the images if possible
- Treatments so far, with dates
- Current medicines
What to do next
Where these numbers come from
Papers
English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions
Trials
ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.
Identifiers and other names
ROR
Tongji Hospital; Tongji Hospital of Tongji Medical College; Affiliated Tongji Hospital; Tongji Hospital Affiliated to Tongji Medical College; Sino-French Branch of Tongji Hospital of Tongji Medical College; Tongji Hospital Affiliated with Tongji Medical College; Tongji Hospital Affiliated to Tongji Medical College of Huazhong; Huazhong University of Science and Technology